Hemoglobin Alc: Structure, Biosynthesis and Clinical Significance In Diabetes Mellitus by Koenig, Ronald J
Rockefeller University
Digital Commons @ RU
Student Theses and Dissertations
1977
Hemoglobin Alc: Structure, Biosynthesis and
Clinical Significance In Diabetes Mellitus
Ronald J. Koenig
Follow this and additional works at: https://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact nilovao@rockefeller.edu.
Recommended Citation














New York, NY 10021-6399
Hemoglobin Alc:
Structure, Biosynthesis and Clinical Significance
In Diabetes Mellitus
A thesis submitted to the Faculty of The Rockefeller University
in partial fulfillment of the requirements
for the degree of Doctor of Philosophy
by






The work described in this thesis was undertaken in the Laboratory
of Medical Biochemistry at The Rockefeller University. I am indebted to
my thesis advisor, Dr. Anthony Cerami, for his guidance, insight and wil­
lingness to explore new fields of biology. I am equally indebted to Dr.
Charles Peterson for showing me the satisfactions and frustrations of
clinical medicine and for his expert guidance during the clinical studies.
Diana Araujo, Dr. Steven Blobstein and Dr. Robert Jones also pro­
vided invaluable assistance and guidance through various parts of this
work. Members of the scientific community outside the Laboratory of
Medical Biochemistry who generously collaborated in this work include
Dr. Joseph Williamson, Dr. Bruce Cunningham, Dr. Christopher Saudek, and
Dr. Thomas Witherup.
The clinical studies described in this thesis were conducted at
The Rockefeller University Hospital, and I am grateful to the entire
Hospital staff for their cooperation in those efforts. I would also like
to thank Judith Seaman and Elizabeth McCracken for their help throughout
this work.
Finally I would like to thank the administrations of The Rocke­
feller University and Cornell University Medical College for instituting
the Biomedical program and affording me the unique opportunity to explore
medical research as a Biomedical Fellow.
iii
ABSTRACT
Diabetes mellitus is a chronic metabolic disorder characterized
by abnormally high blood glucose concentrations and a relative or abso­
lute deficiency of insulin. Approximately 5 per cent of the American
population are afflicted with this disease, which is a leading cause of
morbidity and mortality in the United States today. Diabetes may result
in the dysfunction of many different organ systems, yet the biochemical
mechanism(s) underlying these dysfunctions is unknown. Even the impor­
tance of hyperglycemia in the development of the sequelae of diabetes
is unsettled.
One of the metabolic abnormalities known to characterize this
disease is an increase in the peripheral blood concentration of hemo­
globin Alc. This minor red cell component comprises 3-5 per cent of
the total hemoglobin in non-diabetic humans but up to 15 per cent in
diabetics. There is evidence to suggest that it is a glycosylated de­
rivative of hemoglobin A. The aim·of these investigations has been to
increase our understanding of the significance of increased hemoglobin
Alc concentrations in diabetics.
The studies described here in the diabetic mouse demonstrate
increased hemoglobin Alc to be a marker for the diabetic phenotype re­
gardless of the cause of diabetes. The increase in hemoglobin Alc con­
centration occurs 3-4 weeks after the onset of diabetes. Hemoglobin
Alc is made as a post-synthetic modification of hemoglobin A at a con­
stant slow rate throughout the life of the red cell.
In diabetic humans, hemoglobin Alc concentration correlates with
the severity of disease. Changes in the quality of diabetic control
are followed, after a 3-4 week delay, by proportionate changes in hemo­
globin Alc concentration. Hemoglobin Alc concentration reflects the
mean blood glucose concentration for the 3-4 weeks prior to the measure­
ment. Thus, infrequent hemoglobin Alc measurements would be sufficient
to assess the quality of long-term diabetic control, a feature unique to
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this measurement. The periodic monitoring of hemoglobin Alc concentra­
tion should permit patients to achieve better diabetic control than is
currently possible and should make it possible to determine whether
hyperglycemia is important in the development of the sequelae of diabetes.
The structure of hemoglobin Alc is identical to that of hemoglobin
A, with the addition of l-deoxy fructose attached at the amino terminus
of the B chains. The increased formation of hemoglobin Alc in diabetes
is an example of the increased glycosylation of a protein (hemoglobin A)
occurring in this disease process. The biosynthesis of hemoglobin Alc
provides a conceptual framework that may explain the molecular basis for
many of the sequelae of diabetes. Thus, the abnormal or excess glycosy­
lation of other proteins may cause structural or functional changes in
those proteins and thereby result in the diverse sequelae known to occur
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Diabetes mellitus is a chronic metabolic disorder characterized
by abnormally high blood glucose concentrations and an absolute or rela­
tive deficiency of insulin (Marble). It is a syndrome of unknown etiol­
ogy and variable clinical course, the pathophysiology of which is poorly
understood in biochemical terms.
Despite the fact that diabetes can be defined in only the most
general of terms and very little is known about the basic disease pro­
cess, it is a syndrome cornmon to many animal species (Renold) and has
afflicted man for thousands of years. The earliest known written record
of diabetes in man is in the Ebers papyrus, ca. 1500 B.C. (Marble). In
400 B.C. an Indian, Sushruthra, noted the urine of diabetics to have a
sweet taste, but it was not until 1775 (A.D.) that Dobson demonstrated
this sweetness to be due to sugar. In 1889 von Mering and Minkowski pro­
duced diabetes in dogs by total pancreatectomy. In 1921 Banting and Best
extracted from the pancreas a substance with hypoglycemic properties.
This discovery revolutionized the treatment of diabetes and drastically
altered the clinical course of the disease. Indeed, the administration
of exogenous insulin remains the mainstay of therapy in diabetes. The
introduction of orally active hypoglycemic agents in 1955 added a measure
of convenience to the treatment of many cases of diabetes, although the
use of these agents is still controversial.
Clinical diagnosis of diabetes is based upon measurements of
blood glucose concentrations, and therefore attempts are frequently made
to define the normal limits of glucose metabolism. Yet no standard val­
ues have been agreed upon, largely because carbohydrate tolerance is dis­
tributed in the population as a continuous function (Williams). This
problem has helped produce a large body of conflicting epidemiological
data concerning diabetes. No matter which data one subscribes to, how­
ever, it is clear diabetes is one of the major public health problems in
the United States today_
Estimates of the prevalence of diabetes range from two per cent to
five per cent of the American population (4 million to 10 million cases)
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(Fajans; Diabetes Source Book). Twenty-five per cent of all diabetes re­
mains undiagnosed, and 400,000 new cases are diagnosed each year. Seventy
per cent of diabetes is diagnosed after age 45 and only eight per cent
of all cases are diagnosed prior to age 25. The prevalence of diabetes
increases with age: whereas only one per cent of Americans between ages
18-24 are diabetic, over twenty per cent of the 65-and-older population
have this disease (Diabetes Source Book). Race and sex also bear relation
to the prevalence of diabetes: non-white females have twice the rate of
this disease as non-white males and white males or females. Interesting­
ly, diabetes is ten times as common in the Pima Indians as in the general
United States population, and is virtually non-existent among Eskimos.
Obesity is also a contributory factor to the prevalence of diabe­
tes. In the population 10 per cent above ideal weight, the prevalence
of diabetes is 50 per cent increased between ages 20-29 and 400 per cent
increased after age 60. Furthermore, the more overweight one is, the
greater the risk of becoming diabetic.
The morbidity of diabetes costs the United States 2 billion dollars
per year, 65 per cent of which is accounted for by lost earnings. The
average diabetic loses 15.4 working days per year, compared to 5.7 days
for the general population. Every diabetic has a 67 per cent chance of
being hospitalized in a given year, with an average stay of 5.4 days.
Non-diabetics, on the other hand, have only a 12 per cent annual chance of
being hospitalized, with an average stay of but one day. Eighty-two per
cent of all diabetics visit a physician each year, with an annual average
of 6.6 visits per patient.
The life expectancy of diabetics (at all ages) is only 67 per cent
of that of the general population (Diabetes Source Book). Myocardial in­
farction is the most common cause of death in diabetics (50 per cent of
cases). Clinically significant coronary artery disease is up to 10 times
more prevalent in diabetics than in age-matched controls (Goldenberg).
Renal failure is the other major source of mortality, accounting for death
in nearly 50 per cent of diabetics who suffer from the disease for more
4
than 20 years (Robbins, 1971). In the pre-insulin era ketoacidosis was
the cause of death in 15 per cent of diabetics (Diabetes Source Book);
now it accounts for less than one per cent of diabetic mortality (Fajans).
Cases of diabetes diagnosed before the age of 25 years are fre­
quently classified as juvenile-onset, whereas those diagnosed after age
25 are maturity-onset disease. This division is somewhat arbitrary but
remains useful because the typical clinical course of juvenile-onset dia­
betes differs markedly from that of maturity-onset disease (Wintrobe).
Juvenile-onset diabetics produce little if any insulin of their own and
thus require insulin replacement therapy. Maturity-onset diabetics are
capable of producing their own insulin, and treatment with oral hypo­
glycemic agents (most of which increase endogenous insulin secretion
[Goodman]) may be a suitable therapy. Maturity-onset diabetics are fre­
quently obese, and weight reduction tends to alleviate or eliminate
their disease.
A genetic predisposition exists toward both forms of diabetes
(Tattersall; Nerup), although studies with identical twins (Tattersall)
have demonstrated the predisposition toward maturity-onset disease to be
greater. Attempts at defining the mode of inheritance have led to con­
flicting hypotheses and a general lack of agreement (Stanbury).
Acute environmental insults, such as viral infections, are thought
to underlie many cases of juvenile-onset diabetes. Epidemiological evi­
dence suggests Coxsackie B4 virus can cause this form of diabetes
(Steinke; Craighead). Other viruses, e.g., Mumps, are also known to
infect the pancreas.
The onset of maturity-onset diabetes is usually insidious and
patients may remain asymptomatic for years. Juvenile-onset diabetes is
typically of abrupt onset, with the classical symptoms of polyuria and
polydipsia hailing the onset of the disease. Insulin therapy has virtu­
ally eliminated ketoacidosis as a major cause of morbidity and mortality
in diabetes, but juvenile-onset diabetics remain particularly susceptible
to this complication during periods of hypoinsulinization.
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The introduction of insulin replacement therapy and the advent of
the antibiotic era have greatly extended the lifespan of patients with
diabetes, causing a refocusing of attention on the long-term complica­
tions, or sequelae, of this disease. Diabetes may result in pathological
changes in practically every organ system but those of the large blood
vessels, eyes, kidneys, and peripheral nerves now account for the bulk
of the morbidity and mortality associated with the disease.
Atherosclerotic heart disease is the leading cause of mortality
among diabetics and is as prevalent in pre-menopausal diabetic women as
in diabetic men (Fajans). Although the atherosclerotic process appears
identical to that seen in non-diabetics, for unknown reasons diabetics
suffer from this disease prematurely. Furthermore, whereas the mortality
rate immediately following myocardial infarction is 20-28 per cent in
non-diabetics, diabetics have a 33-58 per cent mortality rate. The five­
year survival of diabetics post-MI is only 17-28 per cent. Clinically
significant atherosclerosis is also common in the arteries of diabetics'
legs. The Framingham study showed intermittent claudication to be 4.5
times as common in diabetics as in the general population (Fajans).
Diabetic retinopathy is the third leading cause of blindness in
the United States, following senile cataracts and glaucoma (Diabetic
Source Book; Fajans). Its prevalence appears related to the duration of
disease rather than age at diagnosis. In patients who have been diabetic
for 24 years the rate of retinopathy is between 42-82 per cent. The
average age at onset of blindness from retinopathy is 60 years, versus
72-78 years for cataracts and glaucoma. Diabetic retinopathy is the
leading cause of blindness among people 41-60 years of age.
Diabetic retinopathy may be classified as non-proliferative (back­
ground) or proliferative. Non-proliferative retinopathy is characterized
by microaneurysms, hernmorhages, hard and soft exudates, edema and in­
creased venous tortuosity. Microaneurysms are sac-like capillary dila­
tions (10-200 �) found most frequently around the edges of areas of non­
perfused, obliterated capillaries. Edema is the most common cause of
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visual impairment in background retinopathy, and presumably reflects in­
creased capillary permeability. Hard exudates represent areas of extra­
vasated protein and lipid and also reflect increased capillary permeabi­
lity. Soft exudates are areas of microinfarction.
Proliferative retinopathy accounts for 6 per cent of all cases
and is characterized by neovascularization. New thin-walled retinal
vessels form, along with connective tissue. Adhesions may occur between
this fibrovascular network and the vitreous body; vitreous contraction
can then result in vitreous hemmorhaging or retinal detachment - the two
major causes of blindness in diabetic retinopathy.
Although the prevalence of senile cataracts is not increased in
diabetes, these cataracts do appear to mature faster in the diabetic
population. Thus, the frequency of diabetics undergoing cataract extrac­
tion is 4-15 times greater than expected (Marble). Diabetes also con­
tributes to glaucoma, the second leading cause of blindness in this
country. Primary open angle glaucoma occurs in 4.8 per cent of diabetics
but only 1.8 per cent of the general population. Glaucoma secondary to
neovascularization of the iris occurs in 10 per cent of all cases of
proliferative retinopathy (Fajans).
Renal failure is the leading cause of death in juvenile-onset
diabetes and accounts for mortality in nearly 50 per cent of cases of
diabetes of 20 or more years duration (Robbins, 1971). The most common
lesions are glomerulosclerosis and arteriolosclerosis. Glomerulosclerosis
initially develops as a diffuse process characterized by mesangial cell
hyperplasia, increased deposition of mesangial matrix, and basement mem­
brane thickening. It is present in at least 90 per cent of patients who
have had diabetes for more than 5-10 years, but is not specific for this
disease.
Nodular glomerulosclerosis (Kirnmelstiel-Wilson lesion) is found in
only 10-35 per cent of diabetics but is pathognomnonic for this disease.
It is characterized by the presence of ball-like intrarnesangial deposits
in the periphery of the glomerulus. The pathological material contains
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mucopolysaccharides, lipids, and collagen, and appears to be chemically
identical to the deposits of diffuse glomerulosclerosis. The diabetic
glomerulus allows excess amounts of plasma proteins to filter into the
urine, presumably because the basement membrane filter does not function
properly.
Arteriolosclerosis is found in both the afferent and efferent
arterioles to the glomerulus, the latter type being specific for diabetes.
The lesion is characterized by hyalin deposits in the arteriolar walls,
narrowing of the lumina and basement membrane thickening.
Although neuropathy is an extremely frequent complication of dia­
betes, its prevalence and resultant morbidity are difficult to estimate.
The most typical pattern of involvement is a peripheral symmetrical
neuropathy of the lower extremities, affecting sensory more than motor
function (Robbins, 1971). Visceral neuropathy may result in bowel and
bladder dysfunction and sexual impotence.
Anatomically the lesions are characterized by segmental demyelini­
zation, implying a Schwann cell defect (Thomas). Early lesions may be
detected by measuring a decrease in nerve conduction velocity. Occlusive
lesions of the vasa nervosa do occur, but are too infrequent to account
for the pathology observed.
Diabetes represents one of the most common and serious threats to
pregnancy today. Gestational diabetes develops in 7 per cent of pregnan­
cies, and by 6 years post-partum 67 per cent of these cases become per­
manently diabetic (Fajans). Toxemia occurs in 4 per cent of non-diabetic
pregnant women but in 20 per cent of diabetics. Perinatal death occurs
in 10-20 per cent of diabetic pregnancies (Fajans; Marble).
The pathological events leading to the organ dysfunctions of dia­
betes are not understood. However, the observation that capillary base­
ment membranes are thickened in the placenta (Burstein), nerve (Fagerberg),
kidney (Farquhar), retina (Bloodworth, 1963), muscle (Benscome) and other
tissues of diabetics has led to the hypothesis that it is this thickening
that accounts for many of the dysfunctions of diabetes (Bloodworth, 1963).
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Routine biopsies of kidneys or retinas for the purpose of assessing base­
ment membrane thickness are not possible, so most studies have utilized
skeletal muscle capillaries for this purpose. Williamson has shown that
some degree of basement membrane thickening normally occurs with aging,
but that compared with those of age-matched controls, the basement mem­
branes of diabetics may be several fold increased in thickness. Basement
membrane disease is essentially non-existent in diabetics whose duration
of illness is less than 6 months, but is present in 80 per cent of all
cases with 20 or more years duration. Capillary basement membrane thick­
ening is segmental and focal in character, perhaps implying that regional
factors are important in its development.
The chemical composition of basement membrane in diabetes remains
unsettled. Renal glomerular basement membrane from non-diabetics is com­
posed of a collagen-like glycoprotein which characteristically contains
22 per cent glycine, 8 per cent hydroxyproline, 2 per cent hydroxy1ysine
and 7 per cent carbohydrate (Spiro, 1968). Glucosylgalactosylhydroxylysine
residues account for 55 per cent of the carbohydrate. Beisswenger has
sho�� that glomerular basement membrane from diabetics is characterized by
a decreased content of lysine with an equivalent increase in hydroxylysine
and hydroxylysine-linked disaccharide units. He postulates this may render
some lysine (or hydroxylysine) residues unavailable for cross-linking and
thus result in the increased permeability that characterizes diabetic
glomerular basement membrane.
Kefalides and Westburg have been unable to corroborate Spiro's data.
They find glomerular basement membrane from diabetics to have a decreased
content of cysteine and sialic acid, but normal levels of lysine, hydroxy­
lysine and glucosylgalactosylhydroxylysine. They argue that a decreased
ability to form disulfide crosslinks may account for the increased permea­
bility of diabetic glomerular basement membranes. Thus, although it is
clear diabetics have more basement membrane than non-diabetics (Klein),
it is uncertain what, if any, chemical abnormalities exist in the diabetic
basement membrane.
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The tissues most commonly affected by the diabetic process (retina,
kidney, nerve, blood vessels, lens) are freely permeable to glucose in the
absence of insulin (Fajans). Thus, unlike adipose and muscle, these tis­
sues will have elevated intracellular glucose concentrations in the dia­
betic state. It is conceivable, then, that excess intracellular glucose
in some way accounts for the sequelae of diabetes.
Recent investigations suggest the metabolism of glucose via the
sorbitol pathway may contribute to certain complications of diabetes,
especially cataracts and neuropathy (Gabbay, 1966; 1973). The sorbitol
pathway consists of two enzymes, aldose reductase and sorbitol dehydroge­
nase, which convert glucose first to sorbitol and then to fructose. Since
neither of these products is capable of leaving the cell and since fruc­
tose is poorly metabolized, hypertonicity and a large osmotic effect
result. Furthermore, the sorbitol pathway results in the oxidation of
NADPH and the reduction of NAO+, which may influence other intracellular
metabolic processes. The in vitro incubation of lens in high glucose or
galactose media results in cataract formation, and inhibitors of aldose
reductase prevent this process from occurring (Chylack). The concentra­
tion of polyol per lens is proportional to the rapidity at which the cata­
racts develop. Aldose reductase is also present in Schwann cells, and
sorbitol and fructose are increased in the sciatic nerve of alloxan dia-
betic rats (Gabbay, 1973).
Intracellular glucose may suffer other metabolic fates in diabetes.
Hyperglycemia results in increased renal UDP-glucose (Spiro, 1976), which
may contribute to the increased glycoprotein (Klein) and glycogen (Ritchie)
production in diabetic kidneys. UOP-N-acetyl-glucosamine is also synthe­
sized in excess in the hyperglycemic state, and this is reflected by an
increased vitreous humor glucosamine content in diabetic rabbits (Walker,
1968) and humans (Walker, 1967). Spiro (1976) hypothesizes that the intra­
cellular metabolism of glucose through insulin-independent pathways in
diabetes results in the production of excess or abnormal glycoproteins, or
some other metabolic abnormality, which then produces the sequelae of
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diabetes. The sequelae would therefore be a direct consequence of excess
intracellular glucose and an indirect consequence of hyperglycemia.
This hypothesis has not been subjected to rigorous testing, largely
because the methodology has not been available to answer even the most
basic of questions, "Does the degree of hyperglycemia correlate with the
presence or severity of the sequelae of diabetes?" Many physicians be­
lieve good carbohydrate control does not decrease the incidence or severity
of the sequelae, and studies addressed to this question have yielded ambi­
guous results (Knowles). Bloodworth (1973) has shown in dogs that good
control of diabetes prevents or retards the onset of cataracts, retinal
microaneurysms, and glomerulosclerosis, but it has not been possible to
undertake comparable studies in humans. The difficulty in determining the
relationship between diabetic control and sequelae hinges on two points:
1. It has not been possible to assess accurately the degree of diabetic
control over the years it takes the sequelae to develop. 2. It is diffi­
cult to quantify the severity of the major sequelae of the disease
(nephropathy, neuropathy, retinopathy).
In order to overcome these problems, I have investigated the synthe­
sis of hemoglobin Alc as a biochemical model for the development of the
lesions of diabetes. In addition, these studies have led to the develOp­
ment of hemogfobin Alc quantification as a means of assessing long-term
diabetic control.
The adult human erythrocyte normally contains several hemoglobin
species. Hemoglobin A, the major component, comprises 90-95 per cent of
the total adult hemoglobin. Hemoglobins Alc (3-5 per cent), A2 (2.5 per
cent), Ala + Ib (1-2 per cent) and F (0.5 per cent) are all minor compo­
nents of the adult red cell population (Bunn, 1976). Hemoglobin Ala + lb
consists of at least two species (Ala' Alb)' but they are rarely
separated and are thus quantified as the sum, Ala + lb' The discovery
that the concentrations of hemoglobins Alc and Ala + Ib are elevated two­
fold in diabetics (Trivel1i) has aroused special interest in the structure
and synthesis of these molecules.
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Hemoglobin Alc has the same amino acid sequence as hemoglobin A
(Holmquist, 1966) but contains, in addition, a sodium borohydride-reducible
blocking group at the amino-terminus of the 8 chain. The blocking group
was presumed to form a Schiff base with the amino terminal valine of the
8 chains. The molecular weight of the blocking group has been reported
to be 180 by mass spectroscopy data (Bookchin) but 280 by chemical analysis
(Holmquist, 1966). Chemical studies (Holmquist, 1966) failed to reveal
the presence of carbohydrate, amino acid, steroid or aromatic groups in
hemoglobin Alc' but mass spectroscopic data (Bookchin) was consistent with
a hexose as the blocking group. Recently it has been shown that acid
hydrolysis of hemoglobin Alc liberates 0.3 moles of hexose, consisting of
glucose and mannose in a 3:1 ratio, per mole of hemoglobin (Bunn, 1975).
This led to the proposal that the blocking group is glucose, and that it
undergoes an Amadori rearrangement subsequent to Schiff base formation.
Although these data could not result in a definitive assignment of
the structure of hemoglobin Alc' they did point strongly toward its being
a glycosy1ated form of hemoglobin.A. Thus, hemoglobin Alc would be another
glycoprotein synthesized in excess in diabetes. Its synthesis would be an
example of the type of process postulated by Spiro to underlie the sequelae
of this disease (see p. 9). The excess production of hemoglobin Alc in
diabetes would be a consequence of the fact that erythrocyte glucose uptake
is insulin-independent and therefore the intracellular glucose concentration
is proportional to the plasma glucose concentration.
Due to the accessibility of blood, studies of the biosynthesis of
hemoglobin Alc could offer a unique way of investigating the biochemical
events leading to the sequelae of diabetes, providing both processes do
proceed via a common mechanism. It is with this goal in mind that these
investigations were undertaken. Hemoglobin Alc was studied with regard to
its biology, clinical significance, and chemistry. The biosynthesis of
hemoglobin Alc in erythrocytes of wild-type and diabetic mice will be de­
scribed in Chapter 2. Chapter 3 details the relationship between hemoglobin
Alc concentration and the quality of diabetic control in human patients.
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The unambiguous determination of the structure of hemoglobin Alc's block­
ing group is described in Chapter 4. Finally, Chapter 5 details the po­
tential significance of this work and future uses of hemoglobin Alc
measurements.
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II. BIOSYNTHESIS OF MOUSE HEMOGLOBIN AIc
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A. Introduction
Many aspects of human diabetes can be investigated with animal
models. In the mouse several mutations are known to result in a diabetic
syndrome. Diabetes may also be induced in wild-type animals by the admin­
istration of specific S-cel1 toxins. Both genetic- and chemically-induced
diabetes mellitus in the mouse appear to mimic the human condition.
The gene db is an autosomal recessive mutation which in the homo­
zygous state on the C57BL/KsJ background results in many of the signs of
diabetes mellitus (Hummel, 1966). The molecular defect is unknown. Early
ln life the homozygote db/db animals are observed to have a marked tenden­
cy for hyperphagia and frank obesity. It is not uncommon to see animals
weighing twice as much as normal mice. During this period of rapid weight
gain db/db mice are normoglycemic and hyperinsulinemic. At approximately
5 weeks of life there is an apparent failure of the pancreas to keep up
with the hypersecretion of insulin necessary to maintain normog1ycemia.
As a result these animals quickly develop many of the signs of diabetes
mellitus: hyperglycemia, glycosuria, polyuria, and polydipsia. These
signs continue unabated until approximately 6 months of age when for un­
kno"� reasons the animals begin to lose weight and eventually succumb.
Although these animals do not develop the pathological lesions of the kid­
ney and retina that are hallmarks of the human condition, they do appear to
develop with time a thickening of the basement membrane of capillaries in
the kidneys (Like). The failure to observe advanced lesions is presumably
due to the fact that these animals die at a relatively early age.
The obese gene (ob) is also inherited in an autosomal-recessive
pattern. When present in the homozygous state on the C57BL/KsJ background,
the ob/ob genotype results in pathology very similar to that observed in
C57BL/KsJ-db/db mice (Coleman). Genetic studies have shown that these
mutations are not alleles (Hummel, 1972) and are located on different
linkage groups (Green).
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In contrast to the above cases, when either the db or ob gene is
present in the homozygous state on the C57BL/6J background, only transient
diabetes results (Coleman; Hummel, 1972). These mice are hyperglycemic
for a few months until pancreatic S-cell hyperplasia and hyperinsulinemia
eventually return the animals to a nearly normoglycemic state. These mice
are hyperphagic and obese throughout their lives, which are of normal
duration.
Two drugs commonly used to induce diabetes in rodents are strepto­
zotocin and alloxan. The structures of these compounds are shown in Fig.
1. The intracellular reduction of alloxan at C5 yields dialuric acid,
which in the presence of molecular oxygen is rapidly reconverted to allo­
xan, plus hydrogen peroxide (Deamer). Alloxan and dialuric acid thus cy­
cle back and forth to generate large amounts of hydrogen peroxide, which
accounts for the cytotoxicity of the drug either directly or through the
formation of free radicals (Heikkila, 1974; 1976).
Streptozotocin is I-methyl, l-nitroso, 3-glucosamine-urea. The
toxicity of this compound is apparently due to the nitrosourea portion
since I-methyl, l-nitrosourea itself results in similar s-cell toxicity,
albeit at a higher dosage (Anderson; Gunnarsson). The glucosamine portion
of the molecule allows specific uptake by the S cells and thus accounts
for the relative specificity of streptozotocin. The toxicity of nitro­
soureas in general, and of streptozotocin in particular, is not well under­
stood, although decreased levels of nicotinamide adenine dinucleotide (NAD)
may playa role. In mice treated with streptozotocin or I-methyl, l-nitro­
sourea a dose dependent decrease in e cell NAD content occurs and cell
killing clearly correlates with the degree of this decrease. Furthermore,
the administration of nicotinamide protects against the diabetogen�c action
of streptozotocin in mice.
The administration of streptozotocin or alloxan to wild-type mice
(Rerup) results in a triphasic response of blood glucose concentration:
a state of acute hyperglycemia is followed by several hours of hypoglycemia










hyperglycemic stage occurs 45 minutes after injection of alloxan and 2
hours after streptozotocin, and is related at least in part to hepatic
glycogenolysis. Degranulation of the B cells, hyperinsulinemia and
hypoglycemia occur 7 hours post-alloxan administration and 10 hours post­
streptozotocin. Chronic diabetes secondary to B cell necrosis is estab­
lished by 24 hours. The severity of diabetes, as assessed by fasting
blood sugar, varies greatly between individual mice, but the diabetes is
always sensitive to exogenous insulin. The major difference between
alloxan- and streptozotocin-induced diabetes is that the former appears
to be spontaneously reversible with time (Bunnag). That is, alloxan
diabetic mice have been noted to replenish their B cell population gradu­
ally over a course of three to six months and return to the normoglycemic
state.
Mice with chemically-induced diabetes are never obese and frequent­
ly weigh less than age-matched controls. The mice may be ketotic and
develop a progressive glomerulosclerosis characterized by mesangial
thickening and the deposition of immunoglobulins and complement.
B. Materials and Methods
Animals. Four-week-old male CS7BL/KsJ and C57BL/6J mice, as well
as diabetic (db/db) and obese (ob/ob) mutants of each strain, were obtained
from the Jackson Laboratory, Bar Harbor, Maine. Six-week-old female
B6D2Fl/J mice were obtained from the same source. Mice were fed Purina
mouse chow ad libitum.
Hemoglobin isolation and quantification. Blood was withdrawn from
the retro-orbital sinus of nonfasted animals in midafternoon, placed in
heparinized tubes, and centrifuged. The plasma was separated from the cells
immediately, stored at -20°C, and later analyzed for glucose. The red blood
cells were washed in five volumes of 0.9 per cent sodium chloride, lysed in
two volumes of distilled water, and saturated with carbon monoxide (Matheson
Gas Products, East Rutherford, New Jersey). Hemoglobin concentration was
determined by the method of Drabkin.
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Hemoglobins (Ala' Alb' Alc' A) were separated by column chromato­
graphy on the methacrylic acid polymer Bio Rex 70 (Bio Rad Laboratories,
Richmond, California). Approximately 13 mg of carbonmonoxy hemoglobin,
50-100 mg/ml, were applied to a 6 rnrn x 25 cm column of the cation-exchange
resin. Hemoglobins Ala' Alb' and Alc were eluted with developer SA
(0.055 M sodium phosphate, 0.01 potassium cyanide, pH 6.8). Hemoglobin A
was eluted with buffer B (0.25 M sodium phosphate, 0.01 M potassium cya­
nide, pH 6.8). The rate of elution was 10 ml/hr, with fractions of approx­
imately 1.2 ml being collected. The elution profile of the hemoglobins
was determined by measuring the absorbance of the fractions at 415 nm.
Hemoglobin components were quantified either by the method of Drabkin or
by measuring the areas under the peaks with a compensating planimeter.
The quantities of the minor hemoglobins are expressed as a percentage of
the total amount of hemoglobin applied to the column.
Glucose quantification. Plasma glucose concentrations were deter­
mined on 5-�1 samples by a glucose oxidase-peroxidase method (Sigma Chemi­
cal Company, St. Louis, Missouri).
NaBH4-reactivity. One hundred microcuries of NaB3H4 (7.1 Ci/rnrnol,
Amersham/Searle, Arlington Heights, Illinois) were mixed with 160 mg of
carrier NaBH4 (Fisher Scientific Company, Fair Lawn, New Jersey). Hemo­
globins A and Alc were reacted separately with this NaB3H4 according to
the method of Bookchin. After extensive dialysis to remove unreacted
NaB3H4, globin was precipitated in acetone-2% HCl at -20°C by the method
of Clegg (1966), and the a and S chains were separated by chromatography
on CM-cellulose (CM52, Whatman, Maidstone, Kent, England) according to the
method of Clegg (1968).
Forty milligrams of the B3H4-reduced globin were applied in 4 ml of
starting buffer (0.005 M sodium phosphate, 0.05 M S-mercaptoethanol, 8 M
urea, pH 6.8) to a 0.9 em x 15 cm column of CM cellulose. The column was
developed with a linear gradient of sodium phosphate, using ISO ml of
starting buffer and 150 ml of limit buffer (0.04 M sodium phosphate, 0.05 M
6-rnercaptoethanol, 8 M urea, pH 6.8). Fractions of 1.2 ml were collected
at a flow rate of 20 ml/hour. The absorbance of the effluent was monitored
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at 2BO nrn. Radioactivity of the fractions was determined in a Packard
Tri-Carb liquid scintillation counter. The fractions containing the 8
chains were pooled, dialyzed extensively against distilled water, and
lyophilized.
Tryptic peptide map of mouse hemoglobin. Two milligrams (0.13 �mol)
of 8 chains isolated from NaB3H4-reduced hemoglobins Alc and A were separ­
ately dissolved in 1 ml of 1 M Tris, 6 M guanidine buffer, pH B.O. A 50
molar excess (6.5 �mo1) of dithiothreitol was added, and the mixture was
incubated for 4 hours at 37°C. The mixture was cooled to room temperature
and 0.5 ml of Tris-guanidine buffer was added, along with 14.3 �mol of
iodoacetamide. The mixture was incubated in the dark for 20 minutes,
dialyzed extensively in the dark against distilled water, and lyophilized.
The samples were then dissolved in 2 ml of 1% NH4HC03 and 0.1 mg of
trypsin (IBO �/mg, Worthington Biochemical Corporation, Freehold, New
Jersey) was added. The reaction mixtures were incubated 4 hours at 37°C,
lyophilized, redissolved in 0.5 ml distilled water, and relyophilized.
The tryptic digests were then dissolved in 0.2 ml of distilled water.
ApproximatelY 0.5 mg of each was spotted onto Whatman 3 MM paper and sub­
jected to electrophoresis at pH 4.7, 3000 V, for 50 minutes according to
the procedure of Clegg (1966). This was followed by descending chroma­
tography in butanol:acetic acid:water:pyridine (15:3:12:10).
The maps were dried and sprayed with ninhydrin (Brenner). Approxi­
mately 5 per cent of each spot was oxidized in a Packard Sample Oxidizer
and counted for tritium. The remainder of the sole 3H-containing spot in
the SAlc map and the corresponding spot in the SA map were eluted with 1:1
pyridine:water and lyophilized to dryness. The samples were digested in
6 N HCl for 16 hours at 105°C in vacuo and analyzed on a Beckman 121 M
amino acid analyzer.
Hemoglobin Alc biosynthesis. ApproximatelY 2 mCi of 59FeC13 (speci­
fic activity 22 mCi/mg; New England Nuclear Company, Boston, Massachusetts)
were added to 1 m1 of mouse plasma. The solution was adjusted to pH 6 with
6.25 N NaOH and injected intraperitoneally into a donor mouse; a total of
20
3 wild-type and 2 db/db CS7BL/KsJ mice were studied. Three days after
the injection of the radioiron, the blood was removed and the specific
activity was determined in a Packard gamma counter (4% efficiency). The
radio-labeled cells (0.20 ml) from each donor were injected via the tail
vein into one +/+ and one db/db recipient. These 10 recipient mice were
then bled at intervals and the specific activities and total cpm of the
hemoglobin fractions were determined. Mice used in the 59FeC13 experi­
ments were 110-120 days old at the start of the experiment.
Chemically-induced diabetes. Diabetes was chemically induced in
eight-week-old wild-type CS7BL/KsJ, CS7BL/6J, and B6D2Fl/J mice with
intraperitoneal injections of either alloxan (Schwartz-Mann, Orangeburg,
New York) or streptozotocin (Calbiochem, La Jolla, California, and a gift
from Dr. W. E. Dulin, Upjohn Company, Kalamazoo, Michigan). Both drugs
were dissolved immediately before use in 0.9 per cent NaCl adjusted to
pH 4.5 with citric acid. Diabetogenic doses of alloxan (300 mg/kg) and
streptozotocin (170 mg/kg) were used. Control animals were injected with
either 0.9 per cent NaCl adjusted to pH 4.5 with citric acid or subdia­
betogenic doses of alloxan (40 mg/kg) or streptozotocin (80 mg/kg).
C. Results
The chromatographic pattern (Fig. 2) of CS7BL/KsJ wild-type (+/+)
mouse hemoglobins closely parallels that of normal human hemoglobins
(Huisman). By convention, the minor human hemoglobins (hemoglobin Ala'
hemoglobin Alb' hemoglobin Alc) are named according to their elution
sequence on Bio-Rex 70; we have followed this same convention in naming
the minor mouse hemoglobins.
Peak 1, which elutes near the void volume, is asymmetric and thus
probably contains at least two hemoglobin species. It is likely that these
hemoglobins are analogous to the human hemoglobins Ala and Alb' which also
separate incompletely on Bio-Rex 70 and elute near the void volume. Mouse
hemoglobin Alc elutes at approximately 10 column volumes and separates




















Fig. 2. Elution profile of hemoglobin from CS7BL/KsJ +/+ mice on Bio Rex
70. Thirteen milligrams of carbonrnonoxy-hemoglobin were eluted
with developer 5A (fractions 1-55) and buffer B (fractions 56-120)
on a 6 mm x 2S cm column. Fractions of approximately 1.2 ml were
collected at a flow rate of 10 ml/hour.
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The structure of mouse hemoglobin Alc was investigated further.
�1ouse hemoglobins Alc and A were reacted with NaB3H4, the heme was ex­
tracted in acetone - 2% Hel, and the a and e chains were separated by
ion exchange chromatography. The elution profile for globin from hemo­
globin AI is shown in Fig. 3. It was found that there is approximatelyc
A
one BH4-reducible linkage per mouse S lc chain (Table I). The a chains
from mouse hemoglobin Alc do not react significantly with NaBH4' nor
does hemoglobin A. Similar results have been obtained with human hemo­
globins Alc and A (Table l).
TABLE I
Moles of B3H4-reducible linkages per mole of hemoglobin monomer















The borotritiide-reduced e chains from mouse hemoglobins Alc and A
were digested with trypsin. The tryptic peptides were separated by a 2-
dimensional analysis using electrophoresis at pH 4.7 followed by descending
chromatography in butanol:acetic acid:water:pyridine.
The peptide maps for BAlc and SA chains are shown in Fig. 4. The
spot with the arrow is the only 3H-containing peptide in the BAlc_map.
It contains 2 x 104 cpm, or 90% of the radioactivity initially spotted
onto the paper. The 3H-containing peptide is in a slightly different posi­
tion compared to the corresponding peptide in the BA map. Amino acid
analysis shows these spots to be the NH2-terminal octapeptides of the eA
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Fig. 3. Separation of a and B chains of NaB3H4-reduced mouse hemoglobin Arc
by ion exchange chromatography on CM-cellulose. Forty milligrams
of globin (prepared by extraction of heme into acetone-2% Hel) were
applied to a 0.9 cm x 15 cm column of CM-cellulose and eluted with
a sodium phosphate buffer gradient (0.005 M � 0.04 M) containing
8 M urea and 0.05 M B-mercaptoethanol, pH 6.8. Fractions of 1.2 ml




Fig. 4. Peptide maps of NaS3H4 -reduced mouse fllc (left) .and f/ (right)
chains after digestion with trypsin. The tryptic peptides were
separated by electrophoresis at pH 4. 7 followed by descending
chromatography in butanol:acetic acid:water:pyridine 15:3:12:10.
The maps were stained with ninhydrin. The sole 3H-containing




Relative amino acid composltlons of the radioactive peptide
from mouse SAlc chains and the corresponding SA peptide,
and the amino acid composition of the
NH2-terminal octapeptide of SA chains (SATI)
Peptides from maps
(3H_)SAIC SA SATl *
Lysine 1.1 1.0 1.0
Histidine 1.1 0.9 1.0
Aspartic, acid 0.9 1.0 1.0
Threonine 0.9 0.9 1.0
Glutamic acid 1.1 1.0 1.0
Alanine 0.9 1.1 1.0
Valine 0.4 0.9 1.0
Leucine 1.0 1.0 1.0
*
(Rifkin)
presumably due to the formation of a borotritiide-reduced modified valine
,that is only incompletely hydrolyzed in 6 N He1. Previous studies with
human fl and SAlc chains have shown their NH2-terminal octapeptides to be
located in a similar position in tryptic digest maps with incomplete re­
covery of the NH2-termina1 valine of the B3H4-reduced SAlc chains
(Bookchin; Rahbar).
Having demonstrated that mouse hemoglobin Alc is structurally ana­
logous to human hemoglobin Alc' we then determined whether diabetic mice
have more hemoglobin Alc than wild-type mice. Although the hemoglobins
of db/db mice (>10 weeks of age) chromatograph similarly to those of
wild-type mice, the amounts of the minor hemoglobins are elevated, as
shown in Table III. Thus, diabetic mice demonstrate a 1.6-fold increase
in peak 1 hemoglobins and a 2.8-fold increase in mouse hemoglobin Alc as
compared to wild-type mice.
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TABLE III
Minor hemoglobins (% of total ± S8-1)






22 1.09 ± 0.05 1.74 ± 0.06
18 1.73 ± 0.11 4.67 ± 0.23
*
>10 weeks of age
**
Difference between db/db and +/? significant (P <0.001)
Mice of the genotype C57BL/KsJ-db/db are normoglycemic (150 mg/dl)
until approximately 6 weeks of age, at which time their plasma glucose
concentrations rise rapidly to reach 500-600 mg/dl (Hummel, 1966). Wi1d­
type (+/+) and db/db mice have identical hemoglobin Alc levels for their
first 10 weeks of life, after which the db/db mouse displays a rapid in­
crease in the amount of hemoglobin Alc (Pig. 5). This rise in hemoglobin
Alc concentration is nearly parallel to, but occurs 3 to 4 weeks after,
the rise in plasma glucose levels (Pig. 6).
The 3 to 4 week time delay between the onset of hyperglycemia and
increase in hemoglobin Alc concentration is a consequence of the mechanism
of hemoglobin Alc biosynthesis.
The biosynthesis of mouse hemoglobin Alc was investigated using
the following experimental design. Wild-type mice were injected with
59pe. Three days were allowed for incorporation of radiolabel into reti­
culocyte hemoglobin. These animals were bled and 0.2 ml of the blood of
each donor animal was injected intravenously into one wild-type and one
db/db recipient. The recipients were then bled at intervals and the spe­
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Fig. 5. Relationship between the percentage of peripheral blood hemoglobin
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Fig. 6. Relationship of both percentage of total hemoglobin as hemoglobin
Alc Co) and plasma glucose C.) to age in C57BL/KsJ - db/db mice.
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It is important to point out that the 59Fe of the donor's red cells
is located only within newly formed reticulocytes (about 2% of red cell
mass). Under ideal circumstances these radio-labeled cells would remain
in the circulation approximately 50 days (Russell). Since the amount of
radiO-labeled blood transferred from donor to recipient (0.2 ml) equals
approximately 10% of one animal's blood volume, only 0.2% of the circula­
ting red cells in any recipient mouse contain 59Fe. Furthermore, unlike
the unlabeled red cells in each recipient, these labeled cells are all
approximately the same age. While the average age of the labeled cells
is constantly increasing, that of the animal's unlabeled cells remains
constant. Thus, any age-dependent change in mouse hemoglobin Alc concen­
tration will not be reflected in the per cent of total hemoglobin as
hemoglobin Alc (since 99.8% of the red cells are of constant average age),
but will be reflected in both the total cpm in the mouse hemoglobin Alc
fraction and the specific activity (cpm/mg) of that fraction.
When the 5 mice which received i.p. 59FeCl3 were bled, the specific
activity of hemoglobin Alc was found to be only 0.33 ± .05 that of hemo­
globin A (Table IV). If hemoglobins A and Alc were synthesized at the
same time in the life of an erythrocyte, they would be expected to have
identical specific activities. (Because hemoglobin A is present in a 25-
50-fold excess over hemoglobin Alc' the gross counts/minute of the two
hemoglobins should not be equal.)
TABLE IV
Specific activities of hemog1obinsAIc and A
in the five donor mice three days after injection of 59FeCl3
Alc
Genotype s.a. Hb Alc s.a. Hb A A
1 +/+ 39,280 108,000 0.364
2 +/+ 17,781 35,560 O.SOO
3 +/+ 11 ,033 45,971 0.240
4 db/db 15,427 51,420 0.300
5 db/db 27,327 120,000 0.228
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The radio-labeled blood from each of these five mice was injected
into one +/+ and one db/db mouse. At intervals these 10 recipient animals
were bled and the specific activities and total counts per minute (cpm)
of hemoglobins Alc and A were determined.
Figs. 7A and 7B display the results of analysis of the specific
activities of the hemoglobins A and Alc from representative +/+ and db/db
animals injected with radio-labeled blood from a +/+ donor. In nine of
the 10 recipient animals the specific activity of hemoglobin A remained
constant or rose slightly over the first 4 to 7 days. This increase is
presumably due to further hemoglobin A synthesis by reticulocytes con-
.. 59F Th b .talnlng e. e 0 served decline in the specific activity of hemoglobln
A, which occurs after 4 to 7 days, is believed due to the destruction of
the highly radio-labeled cells which are damaged by radioactive decay, as
well as injuries incurred during the ex vivo handling of the cells. In
contrast, the specific activity of mouse hemoglobin Alc in all recipients
continued to rise or remained constant for the first 2 to 3 weeks and
then declined at a slow rate.
Since hemoglobin A and hemoglobin Alc are presumably equally dis­
tributed within the radio-labeled cells, it is possible to correct for
premature loss of radio-labeled cells at each time point by dividing the
total cpm of mouse hemoglobin Alc by that of hemoglobin A, which would
remain constant if the radiolytic process were not shortening cell survival.
The data presented in Fig. 8 are a replotting of the information contained
in Figs. 7A and 7B using this technique. From this figure it is seen that
the amount of mouse hemoglobin Alc increases in an approximately linear
fashion for the first 50 days of the life of the red cell. This implies
a constant rate of synthesis.
The rate of hemoglobin Alc production in any recipient mouse can be
estimated by comparing the ratio (cpm hemoglobin Alc/cpm hemoglobin A) �
the time of cell transfer to that ratio after 47 days. These data for all
mice studied are shown in Table V and summarized in Table VI. When labeled
blood from any genotype donor is placed in diabetic recipients, the rate of
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Fig. 7. Specific activities of hemoglobins Alc and A as a function of time
in C57BL/KsJ wild-type (A) and diabetic (B) mice. Wild-type (+/+)
mice were injected intraperitoneally with 2 mCi of 59FeC13. Three
days later approximately 0.2 ml of radio-labeled blood from each
+/+ mouse was injected intravenously into one ./+ (A) and one
db/db (B) mouse. These recipient mice were bled at intervals and
the specific activities of their hemoglobin A and hemoglobin Ale
fractions were determined. Time zero represents the time of the
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Fig. 8. The ratio of total cpm of hemoglobin Alc to that of hemoglobin A
as a function of time in +/+ (6) and db/db (0) mice which re­
ceived radio-labeled blood from a +/+ donor. This figure is a




Hemoglobin Alc synthesis in mice receiving radio-labeled red cells
Donor Recipient (AlC) x 102 (AlC) x 102 � (A;c) x 102Pair genotype genotype A day 0 day 47
1 +/+ +/+ 0.75 3.40 2.65
db/db 0.77 9.10 8.33
2 +/+ +/+ 1. 03 3.46 2.43
db/db 0.86 9.27 8.41
3 +/+ +/+ 0.66 3.18 2.52
db/db 0.60 7.02 6.42
4 db/db +/+ 1.15 4.41 3.26
db/db 1.34 8.74 7.40
5 db/db +/+ 1.11 4.53 3.42
db/db 1.03 9.70 8.67
Ar/A in the colunm headings represents (cpm Hb AI/cpm Hb A).
seen when the cells are transferred to wild-type recipients (Table VI;
P< 0.005). This agrees well with' the 2.8-fold increase in hemoglobin Alc
levels of diabetic mice, as compared to wild type. This production of
hemoglobin AI� must be the result of post-synthetic modification of already
existing hemoglobin A, since de novo protein synthesis is not possible.
Hemoglobin Alc synthesis occurs approximately 2.7 times faster in diabetic
than wild-type mice, even if the red cells in the diabetic originated in a
wild-type mouse. Thus, the rate of synthesis and eventual level of hemo­
globin Alc achieved can be correlated with the genotype and carbohydrate
status of the recipient mouse and not with the genotype of the donor.
In fact, it has been found that increased hemoglobin Alc concentra­
tion is a marker for the diabetic phenotype regardless of the cause of
diabetes or genetic composition of the mouse. Thus, C57BL/KsJ mice that
are homozygous for the obese gene (ob/ob) are diabetic and have a two-fold
increase in their hemoglobin Alc concentration (3.53%, Table VII). However,
when CS7BL/6J mice are homozygous for either the db or ob mutation, only a
transient diabetes results. CS7BL/6J-ob/ob mice that are nondiabetic (and
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TABLE VI
Mean values for hemoglobin Alc synthesis
according to mouse genotype
Number Number
Donor of Recipient of
Hb A * � db/db RecipientIc
genotype Donors genotype recipients HbA � +/+ recipient
db/db 2 +/+ 2 3.34 ± .08 2.40
db/db 2 8.03 ± .64
+/+ 3 +/+ 3 2.53 ± .06 3.05
db/db 3 7.72 ± .65
All 5 +/+ 5 2.86 ± .20 2.74
db/db 5 7.84 ± .42
*
The column heading Hb Alc/Hb A represents (cpm Hb Alc/cpm Hb A) x 102,
Mean ± S. LM.
hyperinsulinemic) have normal levels of hemoglobin Alc (1.86%, Table VII).
Diabetic C57BL/6J-db/db mice have elevated hemoglobin Alc concentrations
(4.50%, Table YII), but when hyperinsulinemia returns these mice to near
norrnoglycemia, their hemoglobin Alc values also approach nondiabetic levels
(Table VIII).
Furthermore, wild-type mice with chemically-induced diabetes have
increased hemoglobin Alc concentrations (3.30%, Table IX). In this experi­
ment, diabetes was induced in 6 mice by the administration of alloxan, and
in 7 mice by the administration of streptozotocin. Both of these drugs
show selective toxicity toward the 8 cells of the islets of Langerhans.
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TABLE VII
Minor hemoglobin components and carbohydrate status
of C57BL/KsJ-+/+, ob/ob, and db/db, as well as
C57BL/6J-+/+, ob/ob, and db/db mice*
Hb Ala + lb Hb Alc Plasma glucose
Strain Mutation N (% ± S.E.M.) (% ± S.E.M.) (mg/dl ± S.E.M.)
C57BL/KsJ +/+ 28 1.15 ± .05 1. 79 ± .04 151 ± 6
db/db .11� eo
(Xl
24 1. 73 ± 4.37 ± .17 551 ± 24
ob/ob 6 1. 55 ± .16** 3.53 ± .28� 472 ± 51�
C57BL/6J +/+ 16 1.35 ± .06 1. 90 ± .11 156 ± 6
468 ± 55�db/db t 6 1. 51 ± .17**
(Xl
4.50 ± .21
ob/ob t 10 2.05 ± .29** 1.86 ± .18** 153 ± 35**
*
Eighty days of age and greater except as noted.
t
80-170 days of age.
353-503 days of age.
Difference statistically signficant, P <0.01, compared with appropriate
wild-type controls.
Difference statistically significant, P <0.001, compared with appro­
priate wild-type controls.
**




Relationship between period of transient diabetes
and Hb Alc levels in C57BL/6J-db/db mice
Hb Alc
N Age (days) (% ± S.E.M.)
6 81-170 4.50 ± .21






Difference statistically significant, P <.01, compared with 81-l70-day­
old group.
**
Difference statistically significant, P <.05, compared with 81-l70-day­
old group.
TABLE IX
Minor hemoglobin and glucose concentrations
in mice with chemically-induced diabetes
Hb Ala + Ib Hb Alc Plasma glucose
Phenotype N (% ± S.E.M.) (% ± S.E.M.) (mg/dl ± S.E.M.)
Normal 13 1.04 ± .10 1.53 ± .13 151 ± 7
Diabetic
Alloxan 6 1.49 ± .21 3.38 ± .46 342 ± 38
Streptozotocin 7 1.49 ± .16 3.22 ± .29 400 ± 30
All 13 1.49 ± .13* 3.30 ± .25** 373 ± 24
**
*
Difference not statistically significant, P >.05, compared with normals.
**
Difference statistically significant, P <.001, compared with normals.
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D. Discussion
Chromatographic analysis on Bio-Rex 70 of mouse hemoglobins
(C57BL/KsJ +/+ and C57BL/6J +/+) revealed several minor components, one
of which had similar chromatographic behavior to human hemoglobin Alc
and comprised 1.5-2% of the total mouse hemoglobin. Although the chemi­
cal structure of mouse hemoglobin Alc is undetermined, it is probably
analogous to human hemoglobin Alc (i.e., a glycosylated hemoglobin)
since both hemoglobins contain a NaBH4-reducible linkage at the amino
terminus of the S chains and have similar chromatographic behavior.
Hemoglobin Alc concentration is increased two- to three-fold in
all mice with genetic- or chemically-induced diabetes, but is not in­
creased in non-diabetic db/db or ob/ob mice. Erythrocytes from dia­
betic db/db mice, when infused into wild-type mice, synthesize normal
levels of hemoglobin Alc' Wild-type erythrocytes circulating in a
diabetic host synthesize hemoglobin Alc at diabetic (two- to three-fold
increased) rates. Thus, the increased hemoglobin Alc concentration of
diabetes is not the result of a genetic defect of the animal or red cell,
nor is it the direct result of obesity, but rather, it is a consequence
of, and a marker for, the diabetic phenotype.
The red cell is an ideal cell type in which to study the time of
protein modification, since there is no protein synthesis in the mature
erythrocyte. Therefore, the appearance of new hemoglobins in the peri­
pheral blood must come about by a postsynthetic modification of existing
hemoglobins. A comparison of the specific activities of hemoglobin Alc
and hemoglobin A of the reticu10cytes from both db/db and +/+ animals
revealed a lower specific activity in the mouse hemoglobin Alc fraction.
This reflects either a greater percentage of the total mouse hemoglobin
Alc than the total hemoglobin A being synthesized in the pre-reticulocyte
state, or the synthesis of hemoglobin Alc from hemoglobin A in the post­
reticulocyte stage. The latter explanation was found to be the case,
since these radio-labeled cells continued to show an increase in the
amount of mouse hemoglobin Alc present whether they circulated in a +/+
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or db/db reclplent. In fact, a linear increase in the ratio (cpm hemo­
globin Alc/cpm hemoglobin A) was observed for 50 days, denoting a constant
rate of synthesis.
The rate of synthesis of mouse hemoglobin Alc was related to the
environment in which the radio-labeled cells were circulating; a faster
rate was observed when the same donor cells (+/+ or db/db) were placed
in a db/db recipient than in a +/+ recipient. Evidently, there is in the
circulation a factor(s) which is normally involved in the formation of
mouse hemoglobin Alc from hemoglobin A. The onset of diabetes causes an
increase in this factor(s) which promotes more rapid hemoglobin Alc
s}�thesis.
The 3 to 4 week time delay between the onset of hyperglycemia in
the C57BL/KsJ db/db mice and the increase in hemoglobin Alc (Fig. 6) can
now be explained. The 59Fe data show hemoglobin Alc to be synthesized at
a very slow rate: only 0.04% of hemoglobin A is modified per day in wild­
type mice, and 0.1% per day in diabetic mice. Thus, hyperglycemia must
be sustained for several weeks before enough new hemoglobin Alc is synthe­
sized to see an increase in the total mouse hemoglobin Alc' The slow con­
version of hemoglobin A to hemoglobin Alc in the mouse red cells has since
been confirmed in human erythrocytes by Bunn (1976). This slow rate of
synthesis will turn out to be a major factor in the clinical utility of
hemoglobin Alc measurements.
The continual linear synthesis of hemoglobin Alc observed for 50
days of the life of the red cell points to a slow, nearly irreversible
reaction. The plateau value of mouse hemoglobin Alc seen in peripheral
blood is brought about primarily by a balance of new synthesis of hemo­
globin Alc and the replacement of old cells laden with hemoglobin Alc by
new cells with less hemoglobin Alc' If the nature of the modification of
basement membrane proteins is similar to that of hemoglobin Alc' then a slow
turnover of basement membrane proteins could easily lead to a substantial
buildup of glycosyl groups in diabetes. In addition, the increase glyco­
sylation could alter the turnover of basement membrane proteins as well as
promote the adherence of other proteins and the eventual thickening of the
basement membrane.
39
III. CLINICAL SIGNIFICANCE OF HEMOGLOBIN Alc
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A. Introduction
Studies in the diabetic mouse demonstrated that hemoglobin A is
glycosylated to form hemoglobin Alc at a constant, slow rate throughout
the life of the red cell. Elevated hemoglobin Alc concentrations appear
to reflect the diabetic phenotype regardless of the underlying cause of
diabetes. The monitoring of hemoglobin Alc concentrations might there­
fore be a potentially useful method of diagnosing diabetes in humans or
of assessing the quality of control in a given patient.
The relationship between hemoglobin Alc concentration and the
clinical syndrome of diabetes was investigated to answer the following
questions. 1) Does the degree of the elevation of hemoglobin Alc concen­
tration correlate with the severity of disease? 2) Will changes in the
quality of diabetic control be reflected by proportionate changes in
hemoglobin Alc concentration? These basic questions were answered in
studies of 32 diabetic out-patients and 5 diabetic in-patients at The
Rockefeller University Hospital.
B. Materials and Methods
Hemoglobin isolation and quantification. The minor hemoglobins
Ala + I band Alc were isolated and quantified from heparinized or EDTA­
treated venous blood as described in Chapter 2, except that the ion
exchange columns were developed with developer 6 (0.055 M sodium phos­
phate, 0.01 M KeN, pH 6.75).
Out-patient study. A total of 32 diabetic out-patients were
studied to determine the relationship between fasting blood sugar,
response to an oral glucose tolerance test, and hemoglobin AIc concen­
tration. The patients ranged in age from 16 to 82 years. Fifteen were
maintained on insulin therapy, 9 on oral hypoglycemic agents, and 8 on
diet alone. Eleven patients were females; 21 were males.
Fasting blood sugars were measured on at least two occasions in
the 32 patients. Oral glucose tolerance tests were performed on 22
patients by giving a 75-gm load of glucose after an overnight fast.
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Glucose concentrations were determined by an AutoAnalyzer (Hoffman). The
response to the glucose challenge was determined by measuring the area
under the curve by planimetry of a three-hour glucose tolerance test.
These studies were approved by the Clinical Review Boards of The Rocke­
feller University Hospital and Washington University School of Medicine,
St. Louis, Missouri.
In-patient study. Five diabetic in-patients were studied at The
Rockefeller University Hospital to determine whether changes in the qual­
ity of control of a patient's diabetes result in proportionate changes
in that patient's hemoglobin Alc concentration. The case histories are
summarized as follows:
Case 1, a 57-year-old black man with an eight-year history of
diabetes mellitus, was maintained on 36 units of insulin per day, and
manifested a mild peripheral neuropathy (by electromyography), with
occasional numbness of the digits.
Case 2, a 38-year-old white woman with a 28-year history of dia­
betes, was maintained on 35 to 40 units of insulin per day. She had mild
peripheral neuropathy and gangrene of the distal phalanx of the right
great toe.
Case 3,. a 38-year-old white woman with a 33-year history of
diabetes, was maintained on 15 to 20 units of insulin per day. In 1970
she underwent hypophysectomy for retinitis proliferans with frequent
vitreous hemorrhages, which had not been controlled by photocoagulation.
She had mild peripheral neuropathy. Her retinopathy has been stable for
four years.
Case 4, a 61-year-old white woman with a 14-year history of dia­
betes, had been treated with phenformin before hospitalization, when she
received 33 units of insulin per day. She weighted 78 kg on admission
and lost 10 kg during hospitalization through a diet and exercise program.
She had retinal microaneurysms and exudates and peripheral neuropathy.
Case 5, a 64-year-old black woman with a 30-year history of diabe­
tes, had received insulin in the past, but had not taken insulin or oral
42
hypoglycemic agents for the two months before admission. She had exten­
sive background retinopathy, peripheral vascular disease, peripheral
neuropathy and mild proteinuria.
All patients were under poor diabetic control at the time of induc­
tion into the study. Blood sugar concentrations were brought to more op­
timal levels within approximately one to two months after hospital admis­
sion. This improvement was accomplished by the careful regulation of
diet, exercise, and the administration of insulin. Patients were hospi­
talized on a metabolic ward for the duration of this study (3 to 6 months
per patient).
Several methods were used to assess the regulation of each pa­
tient's blood sugar concentration. Urinary sugar was measured semi­
quantitatively (on a scale of 0 to 4+) four times per day by standard
methods (Clinitest). A daily average of 1+ is equivalent to approximately
8 grams of urinary glucose/day. These measurements were summed every
seven days to obtain a mean weekly index of the degree of glycosuria. If
a patient's urine frequently gave a negative test for sugar by this tech­
nique, 24-hour urine collections were made three times per week, and the
total sugar content of these specimens was determined quantitatively
(Hoffman). Fasting blood sugar was measured once per week by an Auto-
Analyzer (Hoffman). To assess each patient's response to meals, blood
sugar was measured just before and one hour after each meal for one day
both before and during optimal control of blood sugar levels. These six
blood sugar concentrations were then summed, and this value, called the
glucose brackets, was taken as an estimate of each patient's response to
dietary intake since the diet remained constant during each test. These
studies were approved by the Clinical Review Board of The Rockefeller
University Hospital.
c. Results
Glucose tolerance tests were performed on 22 diabetic patients.
In this group, hemoglobin Alc levels varied from 4.49 per cent to 11.20
per cent. The peak glucose response to the glucose tolerance test ranged
from 184 mg/dl to 880 mg/dl. The correlation coefficient between these
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two variables is highly significant (r = 0.82, P <0.001) (Fig. 9). The
results are unaltered by utilizing the areas under the glucose tolerance
curves (r = 0.76, P <0.001) instead of the peak values. A significant
but less impressive correlation was also found between fasting blood sugar
and hemoglobin Alc levels in the 32 diabetics studied (r = 0.62, P <0.001)
(Fig. 10). Because fasting blood sugar concentration and response to a
glucose tolerance test are interdependent variables that correlate well
with each other (r = 0.77, P <0.001), their respective correlations with
hemoglobin Alc concentration might simply reflect their interdependence.
Partial correlation coefficients (Hays), which take into account the inter­
dependence of response to a glucose tolerance test and fasting blood sugar,
revealed that hemoglobin Alc concentration and response to a glucose toler­
ance test are indeed correlated (partial r = 0.61, P <0.005); whereas the
correlation between fasting blood sugar and hemoglobin Alc concentrations
loses its significance (partial r = 0.22, P >0.05).
These data demonstrate that hemoglobin Alc concentration correlates
with the severity of diabetes, at least as measured by response to an oral
glucose tolerance test.
Five diabetic in-patients were studied to determine whether changes
in diabetic control result in proportionate changes in hemoglobin Alc con­
centration. The patients were poorly controlled at the time of induction
into the study, but were brought to a state of improved diabetic control
during hospitalization (Table X).
The mean fasting blood sugar for the group was 343 mg per deciliter
(range of 280 to 450) at the start of the study and decreased to a mean of
84 mg per deciliter (range of 70 to 100) at the point of optimum control.
The ability to respond to dietary carbohydrate as evidenced by summing of
the blood sugar concentrations measured before and after breakfast, lunch
and dinner (glucose brackets) was also improved. This summed value de­
creased by an average of 51 percent (1865 to 914 mg per deciliter). The
amount of sugar excreted in the urine was also reduced after control.
Semiquantitative estimates of urinary sugar performed four times per day
revealed a decrease of an average of about 90 per cent (mean of 89 to 10)
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Fig. 9. Correlation of hemoglobin Alc concentration and maximal response
to an oral glucose tolerance test in 22 diabetic patients C. pa­
tients treated with insulin, 0 patients treated with oral hypo­
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Fig. 10. Correlation between hemoglobin Alc concentration and fasting
blood sugar in 32 diabetic patients (. patients treated with
insulin, 0 patients treated with oral hypoglycemic agents,
� patients treated with diet alone).
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TABLE X
Changes in minor hemoglobin and glucose measurements
with control of diabetes
Case Fasting Weekly Glucose Hemoglobin Hemoglobin
No. Blood Urinary Brackets t Alc Ala + lb
Sugar Sugar*
mg/dl mg/dl % %
1 :
Precontrol 390 85 1060 10.1 3.5
Control 77 0 718 5.8 2.3
2 :
Precontrol 280 52 1613 6.8 2.5
Control 100 14 1063 4.2 1.9
3:
Precontrol 450 112 2716 12.1 4.8
Control 70 9 653 5.4 2.1
4 :
Precontrol 312 96 1978 10.0 3.2
Control 97 0 918 5.8 2.1
5:
Precontrol 282 100 1959 10.2 3.6
Control 75 28 1218 7.6 3.1
Mean ± S.E.M.
Precontrol 343 ± 33 89 ± 10 1865 ± 270 9.8 ± .8 3.5 ± .4
Control 84 ± 6 10 ± 5 914 ± 105 5.8 ± .5 2.3 ± .2
Normal 70 - 100 0 500 - 800 3 - 5 2
*
Semiquantitative (0 to 4+) urinary sugar concentration was determined
four times per day, and values for consecutive 7 day periods summed
to determine weekly urinary sugar.
t
Sum of blood sugar concentrations measured just before and 1 hour
after breakfast, lunch and dinner.
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when the values 0 to 4+ were summed over consecutive seven-day periods.
Quantitative 24-hour urinary sugar determinations performed three times
per week on several of the patients revealed a similar decrease in
urinary sugar (mean of 33 to 5 g per day).
The concentration of hemoglobin Alc also showed a decrease after
the improvement of control in all patients, from a mean of 9.8 per cent
at the onset to 5.8 per cent at the point of optimum control. Because
the absolute amounts of hemoglobin Ala + lb are small, slight errors in
quantification could obscure changes in the concentrations of these
hemoglobins. Despite this problem, all patients showed a decrease in
hemoglobin Ala + I b levels during control (Table X).
Case 3 responded most dramatically to therapy, decreasing her glu­
cose brackets by 76 per cent (2716 to 653 mg per deciliter) and hemoglobin
Arc by 55 per cent (12.1 to 5.4 per cent). She was also the most hyper­
glycemic patient (fasting blood sugar of 450 mg per deciliter) on admission
to the hospital. Case 2 had the mildest glycosuria on admission and also
the lowest hemoglobin Alc concentration (6.8 per cent); the modest drop to
4.2 per cent is all that would be expected since that value is well within
the limits seen in nondiabetic populations (Trivelli). Of the methods used
in this study to assess blood sugar concentration, the glucose brackets
probably best_reflect mean daily blood sugar levels. The glucose brackets
before and during optimum control of diabetes correlate well with the re­
spective patient's hemoglobin Alc concentrations at those times (Fig. 11),
demonstrating that improvements in diabetes control result in proportionate
decreases in hemoglobin Alc concentration.
The temporal relationship between the decrease in hemoglobin Alc
concentration and improvement in carbohydrate metabolism, as judged by the
weekly summation of semiquantitative urinary sugar determinations, is illus­
trated for one patient (Case 3) in Fig. 12. It can be seen that the de­
crease in urinary sugar precedes the change in hemoglobin Alc concentration
by approximately three to four weeks. The change in the concentration of
hemoglobin Ala + Ib' although smaller in absolute amount, occurs at the same
time as the decrease in hemoglobin Alc levels (Fig. 13).
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Fig. 11. Correlation between hemoglobin Alc concentration and glucose
brackets before and during carbohydrate control in five dia­
betic patients. The glucose brackets represent the sum of
blood sugar levels measured just before and one hour after
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Fig. 12. Temporal relationship between weekly urinary sugar (.) and hemo­
globin Alc (0) levels in Case 3. Semiquantitative (0 to 4+)
estimates of urinary sugar levels, performed four times per day,
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Fig. 13. Temporal relationship between changes in the levels of hemoglobins
Ala + Ib (.) and Alc (0) in Case 3.
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The time lag between changes in glucosuria and minor hemoglobin
concentrations is reminiscent of that seen in the db/db mouse between
the onset of hyperglycemia and the rise in hemoglobin Alc concentration.
It results from the fact that hemoglobin Alc is synthesized at a very
slow rate, so that a change in rate of synthesis must be maintained for
many days before it is reflected by a change in total hemoglobin Alc
concentration.
D. Discussion
The measurements of the concentrations of hemoglobins Ala + Ib
and hemoglobin Alc represent a means of assessing the presence of dia­
betes and monitoring the degree of diabetic control. These minor hemo­
globins serve as indicator molecules that reflect the mean blood sugar
concentration for the previous weeks, not just at the time of measure­
ment. In other words, hemoglobin Alc concentration is not influenced
by short-term fluctuations in blood glucose concentration. Rather,
hemoglobin Alc reflects the patient's mean blood glucose concentration
for the three to four weeks prior to the measurement. Thus, short-term
fluctuations in diet, exercise, emotional status, etc., that greatly
influence fasting blood sugar will not affect hemoglobin Alc' Hemo­
globin Alc could be measured at infrequent intervals in non-fasted
patients to determine whether the patient is well controlled, a feature
unique to this measurement. Currently, clinical assessment of diabetic
control is based on fasting blood sugar and urinary sugar because these
are easy parameters to assess - but they also are not very reproducible
from day to day. Most diabetics are rarely in a position to have these
parameters checked frequently enough for them to know if they really
are well controlled.
The ability of hemoglobin Alc to indicate the carbohydrate status
of the patient over the previous weeks imparts important potential clini­
cal utility to hemoglobin Alc quantification. For instance, this measure­
ment could be used to diagnose diabetes mellitus. At the present time
there are estimated to be more than a million undiagnosed cases of diabetes
in the United States (Fajans). Glucose tolerance tests are too time
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consuming and expensive to identify these cases. Fasting blood sugar
determinations are not reliable for this purpose. A rapid method for
determining hemoglobin Ale concentrations would be useful in screening
large populations for diabetes.
Hemoglobin Ale will be useful in assessing the quality of dia­
betic control and in determining whether carbohydrate control influences
the onset or progression of the sequelae of this disease. This question
remains unsettled largely because it has not been possible to document
the degree of patients' diabetic control on an out-patient basis over the
years it takes for the sequelae to develop. Periodic monitoring of
hemoglobin Ale will circumvent this problem and allow this important
question to be answered.
Hemoglobin Ale should also be useful in determining relative
efficacies of various therapies, such as insulin versus oral hypoglycemic




IV. STRUCTURE OF HEMOGLOBIN Alc
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A. Introduction
Hemoglobin Alc has been shown to be an indicator molecule
whose concentration reflects the patient's mean blood glucose con­
centration for the 3 to 4 weeks prior to the measurement. This re­
sults from the fact that hemoglobin Alc is synthesized at a slow rate,
so that changes in the rate of synthesis must be maintained for several
weeks before the total blood concentration of hemoglobin Alc is signi­
ficantly altered. The potential value of hemoglobin Alc in the assess­
ment of long-term diabetic control is established, but the mechanism of
hemoglobin Alc synthesis and its possible relevance to the glycosylation
of other proteins in diabetes could be understood only after unambiguous
assignment of the structure of this hemoglobin.
Previous work (Holmquist, 1966) has indicated that the amino acid
sequences of hemoglobins A and Alc are identical. The only detectable
difference is a low molecular weight sodium borohydride reducible moiety,
presumably a Schiff base, at the NH2-terminus of the S chain of hemo­
globin Alc. Subsequent work has pointed to a carbohydrate as the modify­
ing group on the SAlc chains (Bookchin). Recently, Bunn (1975) has pro­
posed that glucose is the carbohydrate and that it undergoes an Amadori
rearrangement following Schiff base formation. This proposal was based
on the observation that acid hydrolysis of hemoglobin Alc liberated 0.3
moles of hexose, consisting of glucose and mannose in a 3:1 ratio, per
mole of hemoglobin. In addition to the low recovery of hexose, another
unknown component was liberated under these conditions. These and other
ambiguities in the experimental design and data precluded a definitive
assignment of the structure of hemoglobin Alc.
We investigated the structure of the amino-terminal blocking group
in the following way. Hemoglobin Alc was isolated free of the other minor
hemoglobins and reduced with NaB3H4 to stabilize the molecule and radio­
label the blocking group. The 3H-containing S chains were isolated and a
series of mild enzymatic digestions led to the purification of the amino
terminal modified dipeptide, C3H)-R-valYlhistidine. Comparison by thin
layer chromatography, gas liquid chromatography, and proton magnetic
resonance spectroscopy of R-Val-His with synthetic standards permitted
the unambiguous assignment of the structure of the blocking group.
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B. Materials and Methods
Reagents. All chemicals and solvents were reagent grade. Trypsin,
papain, protease VI and Sil-A (silylating reagent) were obtained from
Sigma Chemical Co., St. Louis, Missouri. The ion exchange resins Bio-Rex
70, AG 50W-X2, AG 50W-X8 and AG I-X8 were purchased from Bio Rad Labora­
tories, Richmond, California; and cellulose phosphates PI and PII from
��atman, Inc., Clifton, New Jersey. Sephadex G-IO was obtained from
Pharmacia Fine Chemicals, Piscataway, New Jersey. Silica gel GF thin
layer chromatography plates were purchased from Analtech, Inc., Newark,
Delaware. L-valyl-L-histidine was purchased from Calbiochem, Los Angeles,
California, NaB3H4 and 14C-valine from Amersham/Searle, Arlington Heights,
Illinois, and 100%-d deuterium oxide, 99.5% pyridine d-5, 99.5% acetic acid
d-4, and sodium-3-trimethylsilylpropionate-2,2,3,3-d-4 (TSP) from Wilmad
Glass Company, Buena, New Jersey.
Isolation of hemoglobin Alc. Blood was drawn from normal human
volunteers into heparinized blasks. The red cells were separated from
the plasma by centrifugation, washed twice with two volumes of 0.14 N NaCl,
lysed by the addition of two volumes of distilled water, and the hemoglobin
solution saturated with carbon monoxide. The carboxyhemoglobin solution
was dialyzed against Developer 6 (0.05 M sodium phosphate, 0.01 M KCN,
pH 6.75) saturated with co. Fifty to 75 grams of hemoglobin (50-75 mg/ml)
were loaded onto a 15 x 50 cm column of Bio-Rex 70 previously equilibrated
with Developer 6. Hemoglobins Ala + lb and Alc were eluted with Developer
6 at a rate of 3 liters per hour; 1.5 liter fractions were collected. The
absorbance of the eluent at 415 nm was monitored to determine the elution
profile. Two to three grams of hemoglobin Alc were isolated. The pH of
the pooled hemoglobin Alc fractions (7 liters) was lowered to 6.4 with
H3P04, and the solution was applied to a 5 x 70 cm column of cellulose
phosphate PI, previously equilibrated with 0.05 M sodium phosphate buffer
pH 6.4 at 4°C. Hemoglobin Alc adsorbed to the resin while contaminating
hemoglobin Ala + lb did not. The column was then brought to room tempera­
ture and the hemoglobin Alc eluted with 0.25 M sodium phosphate, 0.01 M
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KCN pH 7 buffer. This procedure resulted in further purification and a
ten-fold concentration of the hemoglobin Alc.
Isolation of glycodipeptides from hemoglobin Alc. The hemoglobin
Alc solution (2 g in 130 ml) was dialyzed against 0.1 M sodium phosphate
buffer pH 7 and subsequently reacted with a 200 molar excess of NaB3H4
(1.4 x 107 dpm/�mol) at room temperature for 1 hour. After removing the
unreacted sodium borohydride by dialYsis, the heme was extracted in
acetone - 2% HCl at -20°C and the a and 8 chains were separated by ion
exchange chromatography on carboxymethyl cellulose as described in Chapter
2, except that the procedure was scaled up to 600 mg batches of globin on
5 cm x 20 cm columns of the cation exchange resin. The columns were
developed with 8-liter (total volume) gradients of sodium phosphate buffer
and 16 ml fractions were collected at a flow rate of 180 ml/hour.
The absorbance of the eluent was monitored at 280 nm and the radio­
activity of the fractions was determined in a Packard Tri-Carb liquid
scintillation counter. The fractions containing the a and 8 chains were
pooled separately. The (3H-) 8 chains were dialyzed extensively against
distilled water and lyophilized.
The (3H_) 8 chains were dissolved in 1% NH4HC03 to a final concen­
tration of 1 mg/ml and digested for 4 hours at 37°C with trypsin (SO �g/mg
8 chain). The digest was lyophilized, dissolved in distilled water, and
relyophilized.
Partial separation of the tryptic peptides was achieved by ion ex­
change chromatography on the sulfonated polystyrene resin AG 50W-X2
(Schroeder). Six micromoles (90 mg) of digested 8 chains were dissolved
in 2 ml of distilled water, the pH was adjusted to 2 with 6 N HCl, and the
sample was applied to a 0.9 cm x 110 cm column of the cation exchange resin.
The column was developed with a non-linear pH gradient using 350 ml of
starting buffer (pyridine acetate, 0.2 M pyridine, pH 3.1) and 700 ml of
limit buffer (pyridine acetate, 0.2 M pyridine, pH 5.0). Fractions of 2 ml
were collected at a flow rate of 15 ml/hour. The fractions comprising the
3H-containing peak were pooled and lyophilized. This procedure was
repeated three times.
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The (3H_) NH2-terminal octapeptide (SAlcTl) was further purified
(in 3 batches) by ion exchange chromatography on cellulose phosphate PII
(Holmquist, 1964). The samples were dissolved in 2 ml of distilled water,
the pH was lowered to 3 with 3 N HCl and the samples were applied to 0.9
cm x 100 cm columns of resin. The columns were developed at 15 rnl/hour
with a non-linear gradient using 200 rnl of starting buffer (pyridine
acetate, 0.125 M pyridine, pH 4.55) and 400 ml of limit buffer (pyridine
acetate, 0.52 M pyridine, pH 5.5). Fractions of 2 ml were collected and
monitored for radioactivity. The fractions containing tritium were pooled
and lyophilized. Purity of the NH2-terrninal octapeptide (SArCTl) was
assessed by hydrolysis of a portion in 6 N HCl at 105°C in vacuo for 16
hours followed by amino acid analysis (Beckman l19C amino acid analyzer).
The peptide SAlcTl was dissolved (1 roM) in a solution of 0.05 M
NaCN, 0.002 M EDTA and 0.1 M ammonium acetate buffer pH 5.5 and digested
for 16 hours at 39°C by the addition of papain (45 units/�mol peptide).
The NH2-terminal glycodipeptide (glycovalylhistidine) was isolated by ion
exchange chromatography on a O.B x 46 cm column of AG 50W-XB according to
the procedure of Holmquist (1966), except that the glycopeptide was eluted
at Toom temperature using a linear gradient (250 ml total volume) of pyri­
dine acetate pH 5.28, where the pyridine concentration increased from 0.175
M to 0.290 M. - The purity of the glycodipeptide was determined by hydrolysis
in 6 N HCl at 105°C in vacuo for 16 hours followed by amino acid analysis.
Digestion of the glycovalylhistidine with protease VI was not successful
although under similiar conditions complete digestion of valylhistidine
was observed.
Preparation of adducts of valine and valylhistidine with hexoses.
Adducts of various hexoses (D-glucose, D-mannose and D-galactose) with L­
valine were synthesized according to the method of Dixon. Seven millimoles
of l4C-valine (specific activity 1.4 �Ci/mrnol) and 9 millimoles of hexose
were stirred for 3 days at room temperature in 150 ml of pyridine:acetic
acid, 1:1. The solutions were lyophilized and the residues dissolved in
180 ml of 1 M morpholine. A 2S-molar excess of sodium borohydride was
added to each reaction mixture and mixtures stirred for 3 hours at room
temperature. The progress of the reduction was monitored by thin layer
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chromatography on silica gel GF in methyl ethyl ketone:isobutanol:water:
diethylamine (80:80:40:9). The compounds were visualized by spraying the
plate with 0.5% KMn04 in 1 M NaOH. The Rf value of the unreduced adducts
was 0.35 and those of the reduced materials are listed in Table XII. The
reaction mixtures were lyophilized, dissolved in 10 rnl of 0.5 M morpholine
and applied to 2.5 x 50 cm columns of Sephadex G 10. The reduced adducts
were eluted with 0.5 M morpholine and thus separated from the bulk of the
salts and unreacted reagents. Fractions containing the glycitol valines
(reduced adducts) were lyophilized and the oily residues were dissolved
in 150 ml of distilled water. The solutions were made basic (pH 11-12)
by the addition of piperidine and then applied to 4 x 50 cm columns of AG
l-X8 previously equilibrated with morpholine acetate buffer pH 8.6 (0.25 M
morpholine). The adducts were eluted with this buffer in approximately
5 column volumes and lyophilized. The residual morpholine acetate was
removed by repeated evaporations from pyridine on a rotary evaporator
until constant weight was achieved. The products were recrystallized
from ethanol:water (2:1) with an overall yield of 30%.
Glucose (275 �mol) was reacted with L-valyl-L-histidine (180 �mol)
in 2 ml of pyridine:acetic acid (1:1) according to Dixon. The reaction
mixture was lyophilized and the residue dissolved in 1.5 ml of 1 M morpho­
line containing 6.9 mmol of NaB3H4 (2 x 105 dpm/�mol). After 6 hours at
room temperature the material was lyophilized and the unreacted NaBH4 was
quenched with 2 M acetic acid. The material was dried by rotary evapora­
tion, dissolved in 7 ml of 1 M acetic acid and the pH adjusted to 2 with
6 N HCl. The sample was applied to a 0.9 x 100 cm column of AG 50W-X8.
The column was developed with pyridine acetate buffers C (pH 4.21, 0.057 M
pyridine) and D (pH 5.28, 0.11 M pyridine) according to Holmquist (1966),
followed by a linear gradient (400 ml total volume) of pyridine acetate
buffer pH 5.28, 0.175 M to 0.260 M pyridine. Fractions of 2.7 ml were
collected at a flow rate of 10 ml per hour.
Analyses. All synthetic and natural glycopeptides were analyzed by
thin layer chromatography on Silica gel GF using the solvent systems
propanol:water (85:15) and methyl ethyl ketone:isobutanol:water:diethyla­
mine (80:80:40:9). The plates were developed twice and sprayed with either
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0.5% KMn04 in 1 N NaOH, Pauly reagent (Brenner), or ninhydrin (Brenner).
Gas liquid chromatography was performed on the trimethylsilyl derivatives
(Sweeley) of both the glycovalines and glycovalylhistidine methyl esters
(formed in methanolic - 1.5 N HC1). Analysis was performed using a 4 mm
x 6 foot OV-17 column (Supelco Company, Bellefonte, Pennsylvania) in a
Packard 417 gas chromatograph. The gas flow rates were: carrier nitrogen,
45 ml/min; hydrogen flow to detector, 30 ml/min; air flow to detector,
230 ml/min. For analysis of the glycitol valine derivatives the instrument
was programmed from an initial temperature of 175°C with a temperature in­
crease of O.le/minute. The glycovalylhistidine derivatives were analyzed
from an initial temperature of 145°C with a temperature increase of 0.1°/
minute.
All compounds were analyzed at 220 MHz by proton magnetic resonance
spectroscopy employing a Varian HR/NTC-220 proton magnetic resonance
spectrometer having pulse Fourier transform and decoupling facilities.
Two-hundred-fifty-six acquisitions were taken for the naturally-derived
glycodipeptides using a 90° pulse. Solvent for the glycovalines was
deuterium oxide; for the glycovalylhistidines deuterated pyridine acetate
(12 rnM pyridine, pD 6.04) was used. Chemical shifts of the glycitol
valine derivatives are relative to TSP. Acetate was used as internal
reference for_the glycitolvalylhistidines. The chemical shift of acetate
(1.92 ppm, in the pD range employed) was determined using TSP as- an inter-
nal standard and the chemical shifts of the glycitol dipeptides are related
to TSP in this manner.
C. Results
Isolation of glycodipeptides from hemoglobin Alc. The elution pro­
file of hemoglobins Ala + Ib and Alc isolated from the 15 x 50 cm column
of Bio Rex 70 is shown in Fig. 14. Liters 8-15 were pooled and concentrated
by chromatography on cellulose phosphate as described in Materials and
Methods. A portion of this concentrated hemoglobin Alc solution was re­
chromatographed on Bio Rex 70 and demonstrated to be free of hemoglobin
































Fig. 14. Elution profile of human hemoglobins Ala + lb and Alc following
ion exchange chromatography on Bio Rex 70. Seventy-five grams
of carbonmonoxy hemoglobin in 1 liter of developer 6 were applied
to a 15 cm x 50 crn column of Bio Rex 70 and eluted with developer
6 at a rate of 3 liters per hour. Hemoglobin Ala + Ib was eluted
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Fig. IS. Elution profile of purified human hemoglobin Alc following Bio Rex
70 chromatography. Hemoglobin Alc was isolated and purified in
gram quantities as described in Materials and Methods. One milli­
gram of this hemoglobin Alc preparation was applied to a 6 mm x
25 cm column of Bio Rex 70 and eluted with developer 6 (fractions
1-44) and buffer B (fractions 45-60). Fractions of 1.2 m1 were
collected at a flow rate of 10 m1/hour.
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due to loss of the glycosyl group of hemoglobin Alc (hemoglobin A is not
glycosylated).
The hemoglobin Alc was reduced with NaB3H4 and the SAlc chains
were isolated by chromatography on CM-cellulose as shown in Fig. 16. The
3H_SAlc chains were then digested with trypsin, and the 3H-containing,
amino terminal tryptic peptide was partially purified by ion exchange
chromatography on AG 50W-X2, as shown in Fig. 17. Fractions 159-188 were
pooled, lyophilized and rechromatographed on cellulose phosphate Pll
(Fig. 18). Fractions 95-105 of this chromatogram were pooled and lyo­
philized. A portion of the peak was digested in 6 N HCl at 105°C for 16
hours in vacuo and its amino acid composition was determined (Table XI).
The amino acid composition of the 3H-containing peptide agrees well with
the known composition of the amino-terminal octapeptide of S chains from
hemoglobin A (SATl), except that a valine peak was not observed in the
analysis. Instead, a tritium containing peak which was ninhydrin negative
eluted prior to the position of aspartic acid and presumably was a substi­
tuted valine which is stable to acid hydrolysis. Thus, the tryptic pep­
tide isolated is shown to be the �urified NH2-terminal modified octapeptide
of SAlc chains (SAlcT!).
TABLE XI
Amino acid composition of the 3H-containing tryptic
peptide isolated from SAlc chains and the known
amino acid composition of the NH2-terminal octapeptide
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Fig. 16. Separation of a and a chains of NaB3H4-reduced human hemoglobin
Alc by ion exchange chromatography on eM-cellulose. Six hundred
milligrams of globin (prepared by extraction of heme into ace­
tone-2% Hel) were applied to a 5 cm x 20 cm column of eM-cellulose
and eluted with a sodium phosphate buffer gradient (0.005 M �
0.04 M) containing 8 M urea and 0.05 M B-mercaptoethanol, pH 6.8.
Fractions of 16 ml were collected at a flow rate of 180 ml/hour


























Partial purification of the NH2-terminal glyco-octapeptide of
NaB3H4-reduced BAlc chains (BAlcTl) by ion exchange chromato­
graphy on AG sOW-X2. Reduced BAlc chains were digested with
trypsin. Ninety milligrams of the tryptic digest were applied
to a 0.9 ern x 110 cm column of AG sOW-X2 and eluted with a
pyridine acetate pH gradient (pH 3.1 + pH 5.0, 0.2 M pyridine).
Fractions of 2 ml were collected at a flow rate of 15 ml/hour
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Fig. 18. Further purification of reduced BAlcTl by ion exchange chromato­
graphy on cellulose phosphate Pll. The partially purified pep­
tide, obtained by chromatography on AG 50W-X2, was applied to a
0.9 cm x 100 cm column of cellulose phosphate Pll. The column
was developed at 15 ml/hour with a pyridine acetate gradient
(0.125 M pyridine, pH 4.55 � 0.52 M pyridine, pH 5.50). Frac-
tions of 2 ml were collected. Fractions 95-105 were pooled and
analyzed for purity of reduced BAlcTl as described in Materials
and Methods.
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Purified SAlcTl was digested with papain and subjected to chroma­
tography on AG SOW-XB. The elution profile of this chromatogram is shown
in Fig. 19. Two radioactive peaks, in approximately a 2:1 ratio, were
resolved. Amino acid analysis of acid hydrolyzed portions of both of
these peaks gave histidine as the only amino acid, in agreement with the
structure glycovalylhistidine for both naturally derived products (Rl-Va1-
His and R2-Val-His). Four micromoles of Rl-Va1-His (fractions 16l-l6B)
and two micromoles of R2-Va1-His (fractions 172-178) were isolated from a
total of 2 grams of hemoglobin Alc (62.5 �mol S chains), for an overall
yield of 10%.
Preparation of adducts of valine and valylhistidine with hexoses.
Glucose, mannose and galactose were each reacted with 14C-valine in
pyridine:acetic acid (1:1) and reduced with NaBH4. Each reaction mixture
was applied to a Sephadex G 10 column (Fig. 20) to separate the reaction
products from salts and unreacted starting materials. Fractions contain­
ing the (14C-) reduced adducts were pooled, lyophilized, and chromato­
graphed on AG 1-XB (Fig. 21). The major radioactive peak of each column was
lyophilized and the reduced adducts were crystallized from ethanol:water
(2:1). The products were analyzed by thin layer chromatography (TLC),
proton magnetic resonance (pmr) spectroscopy, and gas chromatography (GC)
of their trimethylsilyl (TMS) derivatives. Each hexose resulted in the
formation of � reduced adducts with valine, as shown by the TLC and GC
data in Table XII. The major product (75%) of the glucose and valine
reaction is identical to the major product of the mannose and valine re­
action by TLC and GC. The minor products of these two reactions are also
identical. The two products of the galactose and valine reaction are
clearly different from those of the glucose and mannose reactions.
The pmr spectra confirmed this data. The pmr spectrum of the major
product obtained from the reaction of glucose with valine and the assign­
ment of chemical shifts is shown in Fig. 22. Irradiation of the He multi­
plet of valine at 2.26 ppm caused the doublet at 3.55-3.57 ppm to merge
into a singlet whereas none of the sugar resonances were affected, thereby




















Fig. 19. Elution profile of papain-digested reduced SAlcT1 on AG SOW-X8.
The papain-digested material was applied to a O.S cm x 46 cm
column of AG 50W-XS. The radioactive NHz-termina1 glycopeptide
was eluted with a pyridine acetate gradient (0.175 M pyridine �
0.290 M pyridine, pH 5.28). Two such glycopeptides were re­
covered CR1-Val-His, fractions 161-168 and R2-Va1-His, fractions
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Fig. 20. Partial purification of NaBH4-reduced adduct of glucose and 14C_
valine by gel filtration on Sephadex GIO. The reaction mixture
(See Materials and Methods for details) was applied to a 2.5 cm x
50 cm column of Sephadex GIO and eluted with 0.5 M morpholine.
Fractions of 5 ml were collected at a flow rate of 40 ml/hour.







































Fig. 21. Elution profile of the NaBH4-reduced adduct of glucose and 14C_
valine on AG 1-X8. The peak obtained by Sephadex gel filtration
was applied to a 4 cm x SO cm column of AG l-X8 and eluted with
0.25 M morpho1ine acetate buffer, pH 8.6. Fractions of 9 m1
were collected at a flow rate of SO m1/hour. Fractions 47-70
were pooled and lyophilized, and the reduced adduct recrystal­




Rf values of synthetic and natural glycopeptides and gas
chromatographic data of their trimethylsilyl derivatives
Rf GC Retention
Reactants Products System 1* - System 2 t Time (min)**
Glucose + valine major 0.20 0.29 33.5
minor 0.20 0.36 31.6
Mannose + valine major 0.20 0.29 33.5
minor 0.20 0.36 31.6
Galactose + valine major 0.24 0.32 36.2
minor 0.24 0.40 33.9
Glucose + Val-His peak 1 +t 0.09 0.23
peak 2tt 0.24 0.21 23.0
peak 3tt 0.21 0.17 24.1
----------------- Rj -Va l c li.i s ii= 0.24 0.21 23.0
RrVal-His t� 0.21 0.17 24.1
*
methyl ethyl ketone: iso-butanol: water: diethylamine (80:80:40:9);
two developments
t
propanol: water (85:15); two developments
**
See methods for program conditions.
tt
Gas chromatography was performed on TMS derivatives of the methyl
esters of these compounds.
co
Naturally-derived products isolated from hemoglobin Alc.
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Fig. 22. 220 MHz pmr spectrum of the major product obtained from the
reaction of glucose with valine, followed by NaBH4 reduction.
The spectrum is recorded in D20 using TSP as an internal
standard. Assignment of chemical shifts is based upon pmr





carbon (Ha). Similarly, irradiation of the multiplet at 4.1 ppm (H2,)
converted the two proton octet (AB portion of ABX system) centered at
3.22 ppm into a quartet, establishing the chemical shifts of the HA, HB
and H2, protons. The major product (75%) obtained from the reaction of
mannose and valine had the identical pmr spectrum (not shown). The minor
products of both the glucose and mannose reactions were not isolated free
of the major product, but both mixtures had identical pmr spectra. The
pmr spectra of the two galactitol valine adducts differed significantly
from each other and from the glucitol valine (and mannitol valine)
spectra. These data are consistent with initial formation of a hexose­
valine Schiff base or a1dosylamine linkage followed by an Amadori re­
arrangement (Gottschalk) prior to borohydride reduction (Fig. 23). The
Amadori rearrangement product of the glucose (and mannose) reaction,
prior to borohydride reduction, is l-deoxy, l-(N-valyl) fructose.
Glucose was reacted with valylhistidine, reduced with NaB3H4 and
applied to an AG 50W-X8 column. The elution profile is shown in Fig. 24.
Peak 1 (fractions 110-119) was eluted with buffer D of Holmquist (1966).
Peaks 2 (fractions 258-267) and 3 (fractions 275-281) were subsequently
eluted with the pyridine acetate gradient. Analysis by thin layer
chromatography and gas liquid chromatography indicated glycitolvalylhis­
tidine peaks � and 3 were identical to the naturally derived materials;
Rl-Va1-His and R2-Va1-His respectively (Table XII). Proton magnetic
resonance spectroscopy of these derivatives confirmed this assignment.
The pmr spectra of the naturally derived RI-Val-His and R2-Val-His are
compared in Fig. 25. Assignment of resonances is based on the chemical
shift data of va1ylhistidine and glycitol valine (see above). Small but
distinct differences in the splitting patterns of the sugar protons and
the two AB portions of the spectra were observed. Upon expansion of
these regions, these differences became clearer (Fig. 26). Comparison of
the expanded spectra of the naturally derived Rl-Val-His and R2-Val-His
to those of the synthetically derived glycitol-Val-His peaks 2 and 3


















































The Schiff base adduct between valine and glucose undergoes
an Amadori rearrangement to form I-deoxy, I-eN-vaIyl) fructose.
Borohydride reduction of this compound gives a mixture of the























Fig. 24. AG 50W-X8 chromatography elution profile of the NaB3H4-reduced
adduct formed from the reaction of glucose with valylhistidine.
Glucose (275 �mol) was reacted with Val-His (180 pmol) and the
resulting mixture was then reduced with NaB3H4 (2 x 105 dpm/
�mol) as described in Materials and Methods. The reaction mix­
ture was dissolved in 7 ml of 1 N acetic acid, and loaded onto
a 0.9 x 100 cm column. The materials were eluted as described
in Materials and Methods. Fractions of 2.7 ml were collected
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Fig. 25. 220 MHz pmr spectra of the naturally derived RI-Val-His (upper)
and R2-Val-His (lower). Spectra were recorded in deuterated
pyridine acetate buffer, pD = 6.04. Concentrations were about
1 mM each with 256 accumulations taken. The shaded peaks cor­
respond to pyridine and the' peak at 1.92 ppm corresponds to
acetate, used as an internal reference. Spinning side bands
of HDD are evident in both spectra. Assignment of resonances




Glycitol r volhts peak 2
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R2 -val his
Fig. 26. Comparison of the expanded 220 MHz pmr spectra of the naturally
derived and synthetic glycodipeptides (starting in the upper
left and going clockwise: Rl-Val-His, R2-Val-His" glycitol­
Val-His peak 3 and glyci tol-Val-His peak 2). The "region expanded
is from 2.5 to 4.1 ppm.
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In analogy to the glucose-valine and mannose valine adducts, the
two borohydride-reduced synthetic glucose plus valylhistidine adducts
must be glucitol-Val-His and mannitol-Val-His. The compound from which
they derive, prior to borohydride reduction, is I-deoxy, I-(N-valylhisti­
dinyl) fructose, which results from an Amadori rearrangement of the glu­
cose adduct. Thus, by TLC, GC and pmr spectroscopy, we have shown the
NH2-terminus of SAlc chains to be l-deoxy, l-(N-valyl) fructose.
The adduct of glucose plus valylhistidine found in peak 1 gave a
pmr spectrum qualitatively similar to the above derivatives; the major
difference being that by integration the substance contained 2 moles of
hexose per mole of valylhistidine. The material is tentatively assigned
as containing two hexoses attached at the NH2 group of valine (Gottschalk).
D. Discussion
Holmquist (1966) has shown the structure of hemoglobin Alc to be
identical to that of hemoglobin A except for a low molecular weight boro­
hydride reducible moiety on the NH2-terminal valine of the SAlc chain. It
has been proposed (Bunn, 1975) th�t a glucose molecule is attached to the
valine via a Schiff base which subsequently undergoes an Amadori rearrange­
ment, but a definitive assignment of the structure of the glycosyl group
of hemoglobin Alc has not been made.
In this study hemoglobin Alc was isolated free of hemoglobins Ala
and Alb (which is also glycosylated [Stevens]) by cellulose phosphate ion
exchange chromatography. The hemoglobin Alc was then reduced with sodium
borohydride - 3H and the a and S chains separated. The S chains were
digested with trypsin, and the NH2-terminal glyco-octapeptide isolated was
then further digested with papain. Two chromatographically distinct NH2-
terminal glycovalylhistidine peptides (Rl-Val-His and R2-Val-His) were
then isolated. The mild conditions used in the isolation of RI-Val-His
and R2-Val-His assure that the R groups were not modified (except for
borohydride reduction) prior to identification. Purity of the NH2-terminal
glycopeptides isolated was assessed after each enzymatic digestion. The
NH2-terminal glyco-octapeptide was shown by amino acid analysis to be
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derived solely from hemoglobin (Table XI). Similarly, the amino acid
sequence of the glycodipeptides isolated was valylhistidine - the sequence
at the NH2-terminus of hemoglobin e chains. Thus, non-heme proteins that
are known to contaminate hemoglobin Alc isolated by ion exchange chroma­
tography on Bio-Rex 70 (Bunn, 1976) could not have been the source of
RI-Val-His and R2-Val-His.
The structures of the naturally derived, pure Rl-Val-His and R2-
Val-His were compared with model compounds. Adducts of glucose, mannose
and galactose with valine were synthesized, reduced with NaBH4 and puri­
fied. Each hexose resulted in the formation of two reduced adducts. The
fact that two reduced adducts were obtained and that the glucose and
mannose adducts were identical is consistent with intial information of
a hexose valine Schiff base or aldosylamine linkage which undergoes an
Amadori rearrangement (Gottschalk) prior to reduction. The Amadori re­
arrangement product formed from the adducts of both glucose and mannose
with valine is I-deoxy, l-(N-valyl) fructose. Subsequent reduction with
NaBH4 is not stereospecific and therefore generates 2 C2, isomeric
products (Fig. 23). In a similar fashion the reaction of glucose with
valylhistidine was found to yield, after borohydride reduction, both
glucitol and mannitol valylhistidines. These products were separated
by ion exchange chromatography and shown to be identical by gas liquid
chromatography, thin layer chromatography (Table XII), and pmr spectro­
scopy (Fig. 26) to RI-Val-His and R2-Val-His obtained from hemoglobin Alc'
Thus we conclude that hemoglobin Alc has, as the NH2-terminus of the e
chain, l-deoxy, l-(N-valyl) fructose.
Assignment of the configuration at C2, of Rl-Val-His and R2-Val-His
has not been attempted although it would be of general interest. However,
in situ or in vivo, the material exists in a keto or hemiacetal form and
only subsequent to borohydride reduction is the asymmetric C2, center
generated. Of greater interest would be the configuration of the carbo­




The aim of these investigations has been to increase our under­
standing of the significance of increased hemoglobin A concentrationsIc
in diabetes mellitus. Hemoglobin A is a glycosylated hemoprotein thatlc
comprises 3-5 per cent of the total hemoglobin in non-diabetic humans
and 1.5-2 per cent in wild-type mice. Its concentration is elevated
approximately two-fold in diabetic humans and mice.
The studies in the mouse reported here have demonstrated increased
hemoglobin Alc to be a marker for the diabetic phenotype regardless of
the cause of diabetes (genetic defect, environmental insult). Hyper­
glycemia precedes by 3 to 4 weeks the increase in hemoglobin Alc. Hemo­
globin Alc is made as a post-synthetic modification of hemoglobin A at a
constant slow rate throughout the life of a red cell.
In diabetic humans hemoglobin Alc concentration correlates with
the severity of disease, as assessed by response to an oral glucose
tolerance test. Changes in quality of diabetic control are followed,
after a 3 to 4 week delay, by proportionate changes in hemoglobin Alc
concentration. Hemoglobin Alc concentration appears to best reflect the
mean blood glucose concentration for the 3 to 4 weeks prior to the
measurement. This is a result of the slow rate of hemoglobin Alc synthe­
sis, so that changes in rate of synthesis must be maintained for many
days before the total hemoglobin Alc concentration is significantly
altered. Thus, infrequent hemoglobin Alc measurements are uniquely
capable of assessing the quality of long-term diabetic control.
The structure of hemoglobin Alc is identical to that of hemoglobin
A, with the addition of I-deoxy fructose attached at the amino terminus
of the 8 chains. The origin of this unusual hexose is apparently glucose,
which forms a Schiff base adduct with the amino-terminal valine and sub­
sequently undergoes an Amadori rearrangement to yield the l-deoxy fructose
product. Stevens has shown that, in vitro, hemoglobin A and glucose do
not readily form an adduct. However, glucose-6-phosphate does react with
the amino terminus of the e chains of hemoglobin A to form an adduct which
has the same pI as hemoglobin Alb. It is conceivable that, in vivo,
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hemoglobin Alb is then dephosphorylated to yield hemoglobin Alc' Apparent­
ly, the phosphate group is necessary to orient and stabilize the glucose
moiety in the DPG pocket of hemoglobin to allow adduct formation.
These data point to a dual role for hemoglobin Alc measurement in
the management of diabetic patients and research into the basic disease
process. The stability of hemoglobin A concentration to short-termlc
fluctuations in blood glucose levels makes its quantification an excellent
means of assessing the presence of diabetes and of monitoring the degree
of long-term diabetic control. Blood sugar determinations are not suffi­
ciently reproducible to allow accurate assessment of control and are not
sensitive enough to diagnose many cases of diabetes. Glucose tolerance
tests are too time-consuming and expensive to be of general use in this
regard. A rapid assay for hemoglobin Alc would be useful in screening
large populations for diabetes mellitus and would permit the evaluation
of diabetic control on an outpatient basis in a more objective and accurate
fashion than is now possible. In addition, serial hemoglobin Alc measure­
ments on an out-patient basis should make it possible to readdress the
long debated question of whether control of glucose metabolism influences
the development of sequelae.
The pathogenesis of the sequelae of diabetes remains one of the
major unsolved mysteries of this disease. Perhaps the increased glycosy­
lation of hemoglobin is a reflection of a mechanism that also accounts for
the clinical complications of diabetes. That is, diabetes might be a
disease of generalized abnormal protein glycosylation. Just as hemoglobin
can be glycosylated in excess in diabetes to form increased hemoglobin Alc'
other proteins might be similarly modified by this disease process. The
abnormal glycosylation of these proteins might result in altered enzymatic
activity, solubility, etc., and thus lead to the sequelae of diabetes.
(The glycosylation of hemoglobin does result in functional changes, e.g.,
an increase in oxygen affinity [Bunn, 1970]).
This hypothesis leads to an interesting prediction. Even if the
patient is hyperglycemic, a cell that requires insulin for glucose entry
will not have an elevated intracellular glucose concentration in the
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diabetic state. Only cells that are freely permeable to glucose in the
absence of insulin will contain excess glucose, and it is therefore in
these cells that we would expect increased protein glycosylation and
consequent functional impairment.
As Spiro (1976) was first to point out, the tissues that are most
commonly affected by diabetes - lens, nerve, glomerulus, blood cells and
aorta, for instance - are insulin-independent for glucose uptake. It will
be necessary to investigate the structure and carbohydrate content of
proteins in these tissues in poorly controlled and well controlled dia­
betics to determine whether abnormal protein glycosylation can indeed
account for the sequelae of this disease.
If abnormal protein glycosylation is a general phenomenon in dia­
betes, the chemistry of the modification will probably vary with the par­
ticular protein and tissue involved.
The postsynthetic modification of the B chain of hemoglobin A is
highly specific and is probably contingent upon the relatively low pK of
the amino terminus of this protein (Garner) as well as the peculiar
affinity of organic phosphates (e.g., glucose-6-phosphate) for the DPG
pocket of hemoglobin. Other proteins may form glycosylated Schiff base
adducts at amino groups which similarly possesss the right combination
of pKa and steric factors. Amino terminal residues and basic amino acid
side chains would both be candidates for such a process.
The Schiff base-Arnadori rearrangement class of adduct discussed
above probably would form non-enzymatically. However, it is also possible
that enzymatic protein glycosylations would increase in the hyperglycemic
state. Studies with genetic and chemically-induced diabetic mice (Spiro,
1971; Khalifa; Velasco) have demonstrated increased activities of renal
cortical lysyl hydroxylase and glucosyl transferase, two enzymes important
in the glycosylation of basement membrane collagen. Although controver­
sial, Beisswenger has found diabetic glomerular basement membrane to have
an increased percentage glucosylgalactosyl-hydroxylysine residues.
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The deposition of glycogen has been observed in the renal tubules
of uncontrolled human diabetics (Ritchie) and alloxan diabetic rats
(Robbins, 1950). In the latter the severity of the process reflects the
degree of hyperglycemia and can be reversed by lowering the blood glucose
level. An elevated glucosamine content of vitreous humor glycoproteins
has been found in diabetic rabbits (Walker, 1968) and this defect also
corrects toward normal with control.
These glycosylation reactions are all clearly a function of blood
(and intracellular) glucose concentration. While the chemical reactions
themselves are all probably irreversible, the half life of the particular
protein and tissue involved would determine the reversibility of the
consequent lesion. The relatively rapid turnover of blood cells accounts
for the reversibility of diabetic sequelae in these cells (Peterson).
Basement membrane glycoproteins turn over at an exceedingly slow rate
(Spiro, 1976) and therefore a substantial buildup of glycosyl groups in
this matrix would take longer to occur but would also be more difficult
to reverse. In all cases, normalization of blood glucose levels would be
necessary for the prevention and/or regression of the lesions of diabetes.
Thus, studies of the glycosylation of hemoglobin might provide a
unifying model for the development of the sequelae of diabetes as well as
provide a clinical tool for monitoring diabetic control. Hopefully,
clinical measurement of hemoglobin Alc will allow the patient to achieve
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